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Abstract 
 
Causes of gastrointestinal diseases such as ulcerative colitis (UC) Crohn’s 
disease (CD) and irritable bowel syndrome (IBS) are not yet completely 
understood and clinical investigation for diagnosis is invasive, costly and time 
consuming.  Disease may originate from the host or in combination with 
commensal enteric bacteria, notably sulphate reducing bacteria.  Examination of 
volatile compounds from clinical samples may provide indicators and better 
understanding into aetiology of these conditions and provide biomarkers for 
individual disease.   
A total of 91 volunteers from Addenbrooke’s Hospital consisting of controls and 
diseased patients pre and post treatment provided clinical samples of breath, 
blood, urine and faeces.  Analysis using GC-MS and SIFT-MS provided a wealth 
of compounds for identification as potential markers which can be used as 
biomarkers to provide a rapid non-invasive, cost effective method for monitoring 
and disease diagnosis.  
Clinical samples of breath, blood, urine and faeces from all 91 volunteers were 
analysed by GC-MS and compound identification was made for each sample with 
Automated Mass spectral Deconvolution and Identification System (AMDIS) and 
comparison with the National Institute of Standards and Technology library (NIST 
v.2).  Compounds were identified for all the clinical matrices providing a vast pool 
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of information for data processing.  From initial observation of all the clinical 
matrices faeces produced the largest numbers, typically several hundred on a 
single chromatogram.  A method of data reduction for manageable data handling 
was required and a careful selection criterion to make accurate choices of 
compounds was produced.   The three methods for selection to provide a list of 
‘candidate compounds’ were: 
1. Most abundant 
2. Most probable based on learned literature 
3. Visual inspection of a representative subset of chromatograms  
The selection process provided a short-list of thirteen ‘candidate compounds’ 
chosen from pre and post treatment faecal samples.  Initially the compounds 
were compared using Box and Whisker plots for each control and disease groups 
to show outliers, quartiles and median ranges.  Kruskall-Wallis analysis of 
variance showed that the ethyl esters of propanoic and butanoic acid, butanoic 
acid, butanioc acid methyl ester, 3-methyl butanoic acid, 1-butanol, 1-propanol 
and indole were statistically significant.   Mann-Whitney U test was performed on 
these compounds to show pair wise comparisons to identify differences between 
groups.  All eight compounds showed a significant difference between pre 
treatment CD and the control group, and the number of compounds that had 
significance was less for UC and IBS.  Far fewer significant differences were 
found between pairs of disease or disease/control groups for post treatment than 
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pre disease indicating the post treatment groups were more similar to the control 
groups and that these compounds are potential indicators for disease.  The same 
candidate compound selection was made for breath, blood and urine and the 
same statistical analysis performed as for faeces.   Unlike the faecal samples it 
was found that these compounds were absent in many of the breath, blood and 
urine samples and generally not often detected, therefore demonstrating that 
faeces provide the most reliable range of compounds for detection of disease 
states. 
From the eight compounds two were chosen for GC-MS method development.   
Butanoic acid methyl ester (methyl butyrate) and propanoic acid ethyl ester 
having similar retention times between12 and 13 minutes.  Pure samples of each 
were easily obtainable from Sigma-Aldrich.   A range of dilutions of each 
compound was made to provide regression lines from which the lower limit of 
detection (LLOD) could be calculated.    Accurate quantification can then be 
made from the regression line for each compound.  The modified method 
provided a more rapid analysis time which would be favourable for a diagnostic 
test.  These compounds showed potential as diagnostic markers for disease.  
The other six statistically significant candidate compounds could be treated in the 
same way to provide quantification, LLOD and retention time. 
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Chapter 1 and Literature Review 
 
1.1 Introduction  
 
Gastrointestinal disease is identified as a group of debilitating disorders that often 
leads to chronic ill health and can severely reduce quality of life and sometimes 
life expectancy.  Aetiology of diseases in this investigation is, to date, poorly 
understood and treatment for patients is often not very effective.  This Masters by 
Research (MRes)  was undertaken as part of a larger project being funded by the 
Wellcome Trust principally for the investigation of sulphate metabolism by 
sulphate reducing bacteria in inflammatory bowel disease (IBD).  It was 
hypothesised that IBD causes changes or is caused by changes in gut flora and 
that these changes can be detected through the signature of volatile organic 
compounds (VOCs).   
VOCs are carbon containing compounds commonly produced by metabolic 
processes and found in the environment in the form of paint and adhesives that 
evaporate readily at ambient temperature and pressure.  They are present as 
trace compounds in breath and above the headspaces of clinical samples and 
once captured can be detected by analytical equipment.   Identification of specific 
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VOCs might enable them to be used as biomarkers for the development of 
alternative diagnostic tests.   
IBD covered in this research appears to have a dysfunction in the metabolism of 
suphates and sulphides with the production of hydrogen sulphide (H2S) which is 
cytotoxic in humans.  This causes the epithelium to become inflamed resulting in 
structural damage to the gastrointestinal (GI) tract (Picton, et al., 2007).   
Crohn’s disease (CD), ulcerative colitis (UC), and irritable bowel syndrome (IBS) 
are collectively known as IBD and although each is aetiologically different, the 
symptoms can often appear similar.  The causes of gastrointestinal disease have 
not yet been fully identified, but may involve a genetic susceptibility of the 
individual concerned or mutation or genetic modification of gastrointestinal 
bacteria.  Environmental factors, lifestyle and stress appear to exacerbate the 
conditions and combinations of each of the factors involved make it difficult to 
single out a primary cause (Walter,et al., 2006). 
Current investigation and diagnosis (See Section 1.4.6) for IBD is often time 
consuming, invasive and costly and a cheaper non-invasive alternative would be 
a great advantage.  Technology into identification of VOCs has greatly improved, 
and a wealth of research has been carried out, potentially leading to new 
methods of disease monitoring and diagnosis (Smith and Španĕl, 1996).   
Malodour from breath has been used as a health indicator for hundreds of years, 
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by physicians observing the smell.  Advanced technology has identified 
biomarkers from breath, potentially for a rapid diagnosis of identifying disease by 
using portable devices in clinical practices (Miekisch and Schubert, 2006).   
Analytical tools, such as Gas Chromatogram-Mass Spectrometery (GC-MS) and 
Selected Ion Flow Tube-Mass Spectrometery (SIFT-MS) can detect many 
hundreds of volatile compounds from breath and other clinical samples such as 
blood and urine (Cao and Duan, 2006).   Technology is moving towards VOC 
analysis as a potential route; portable monitoring devices may be seen in 
outpatient clinics to measure trace compounds from breath samples or from 
headspace above a clinical sample to provide a rapid and non-invasive test for 
IBD identification. 
The samples for this study were provided by volunteers from Addenbrookes 
Hospital in Cambridge.  Details are described in Chapter 2, Section 2.1.1. A list 
was subsequently sent to Cranfield with information on age and gender which 
has been interpreted and added to the Results and Discussion Chapters.  
 
1.2 Healthy Gut 
 
We generally do not take much notice of our digestive systems until something 
goes wrong; food goes in at one end and faeces come out of the other. The 
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gastrointestinal tract is designed to process food into simple soluble substrates to 
provide heat and energy for growth, and repair to the body.  Digestion starts in 
the mouth where teeth cut and grind food, with enzymes such as amylases 
present in saliva to break down large molecules.  The stomach processes food 
with peristaltic motion from its muscular walls and secretes gastric juices turning 
the food into a semi-fluid state called chyme.  This partially digested food enters 
the first part of the intestine, the duodenum, where bile salts and pancreatic 
juices break down starches, proteins and fats into smaller molecules.  The 
resulting watery emulsion, chyle, containing amino acids, fatty acids and glucose 
enters the small intestine where absorption of these small molecules occurs 
through the gut wall and into the bloodstream (Roberts,1976). The large intestine 
or colon, mainly absorbs water and some vitamins, and active transport moves 
sodium and chloride ions through the luminal wall.  It is this part of the 
gastrointestinal tract that this project proposes to study.  The structure of this 
organ has been well investigated, but there are still gaps in our knowledge of 
how it functions, identification of all gut bacteria and what causes disease to 
occur.  
The colon is the final part of the digestive tract comprising of a convoluted tube of 
about 1.5 metres in length.  Retention or transit time for food in the 
gastrointestinal tract is on average 60 hours for normal healthy individuals,   
(Cummings and Macfarlane, 1991).   
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 1.2.1 Gastrointestinal Bacteria 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Diagram showing type of intestinal flora found in each section of 
the GI tract (from web page1) 
 
The environment within the large intestine is favourable to vast numbers of living 
bacteria with densities of up to 1012 cells/g of luminal content and up to 500 
different species maintaining a dynamic microbial ecosystem of which two thirds 
of faecal matter is made up from bacteria (Guarner and Malagelada, 2003).  As 
shown in Figure 1 the majority of bacteria and the greatest diversity of species 
are found in the colon.  Many different types of gut bacteria have been identified 
but collecting a sample from a particular region of the GI tract as a practical 
Key for Figure 1 
Numbers represent 
micro-organisms/g 
luminal content 
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application of obtaining an ‘uncontaminated’ sample is not straightforward.  It 
may be easy to obtain an excreted faecal sample to study, but obtaining samples 
from other areas of the gut is invasive as it would require a colonoscopy.   Gut 
microorganisms are non-spore forming anaerobes and the most abundant are 
Bacteriodes, Eubacterium and Bifidobacterium.  Also a number of gram-positive 
anaerobes such as cocci, clostridia, enterococci and enterobacteriaceae are 
common (Simon and Gorbach, 1984).  Hydrogen metabolism in the gut often 
takes one of two routes: as observed from figures from the industrialised world, 
between 30 and 50% of people harbour methanogenic bacteria and others carry 
sulphate reducing bacteria.  As a consequence people that have more 
methanogenic bacteria produce methane while sulphate reducing bacteria 
carriers produce hydrogen sulphide which is extremely toxic to humans, probably 
because it reacts with essential proteins (Tangerman, 2009).  Strains of 
Escherichia coli have been observed to be more common in patients with IBD 
than in control patient groups (Xavier and Podolsky, 2007).  
 At birth the large colon is sterile, but soon becomes colonised with micro-flora 
from the mother and surrounding environment, determining the individuals’ 
lifelong gut flora make-up. The balance between the species and numbers of 
micro-organisms generally remains in equilibrium throughout life and when the 
individual is in good health.   Normally, the microorganisms have a symbiotic 
relationship with the host and many of which have been identified as having 
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useful functions in maintaining health by assisting the immune system.   
However, for some people there are factors that affect this balance, varying from 
stress to a genetic susceptibility (this can be the genetic make up of the host or 
from the resident bacteria), or from environmental triggers such as allergy to 
foods, medication, diet or infection resulting in bacterial species and numbers 
drastically altering and remaining so for periods of time.  This often has a 
deleterious effect on the health of the gut lining and consequently the general 
health of the person.  
 
Figure 2  Cross-section diagram of the gut wall showing mucin layer (in 
green) covering the epithelial layer and bacteria most abundant in the 
colon (From Web page2) 
 
 
1.2.2 The Sulphomucin layer and the Immune Response 
 
Sulphomucin layer 
Lamina 
propria 
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As seen from Figure 2 sulphomucin is a lubricating substance, providing a 
protective mucosal barrier for the luminal epithelial wall against direct contact 
from the passage of digestive material, digestive enzymes, bile salts, bacteria 
and the products of microbial fermentation.   Protection is also required from 
digested materials such as hypertonic saline, ethanol and non-steroidal anti-
inflammatory drugs (Allen, 1989) 
The composition of sulphomucin is a protein backbone with large numbers of 
oligosaccharides attached at different points to the backbone with disulphide 
bridges as seen from the diagram of the sulphomucin molecule in Figure 3. 
There are two groups of mucin, one that is secreted and the other is membrane 
bound, the chemical composition also varies as some have acidic and some 
have sulphate groups attached to them.  There are four major mucins present in 
the colon and rectum.  They are MUC1, MUC2, MUC3 and MUC4 and have 
different functions and are apparent at different stages in life.  Small peptide 
chains or trefoils within the mucin are involved in epithelial protection and 
mucosal healing (Shirazi, et al., 1999). 
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Figure 3 Diagram of a sulphomucin molecule (From Web page 3) 
 
The gastrointestinal immune system has evolved for protection of the epithelium 
from bacterial invasion and for absorption of nutrients into the bloodstream 
(Helgeland and Brandtzaeg, 2000).  A symbiosis exists between host and colonic 
bacteria which influences the health and immune response of the host, especially 
when products of bacterial metabolism protect the luminal lining (Garner, et al, 
2007).  Butyrate is an end product of colonic fermentation by bacteria and is 
associated with a beneficial effect on the mucosa and colonic health (Hamer, et 
al, 2010).  
When symbiosis is disturbed, macrophages, neutrophils and T cells become 
activated and produce pro-inflammatory cytokines.  In a normal state the gut is 
mildly inflamed due to everyday breakdown and repair of tissue.  The equilibrium 
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is lost if the pro-inflammatory cells outnumber the anti-inflammatory benefit and 
inflammation to the gut occurs (Singleton, 2005).  When inflammation is present 
the permeability of the epithelium is increased and the protective barrier is 
broken down.  Pro-inflammatory cells have been shown to be produced during 
episodes of inflammatory bowel disease, consequently immunomodulators and 
immune-suppressive drugs are used for treatment (McFarland, 2008). 
Characteristics of the sulphomucin layer have been observed to vary in disease, 
affecting thickness and composition by a defect of the fatty acid metabolism in 
colonocytes has been seen in patients with UC (Gibson, et al., 1993).  CD is 
known to have granulomas caused by aggregation of macrophages.  It is 
commonly found in the terminal ileum and unlike UC is patchy and segmental 
and inflammation traverses through the epithelial layer (Xavier and Podolsky, 
2007).  
Coeliac disease and rheumatoid arthritis are both autoimmune inflammatory 
diseases.  Coeliac disease affects the small intestine brought about by ingestion 
of gluten for susceptible individuals.  Sometimes defined as ‘gluten-sensitive 
enteropathy’, it is lifelong and if left untreated can be very detrimental to health 
(Holmes,1987).  Rheumatoid arthritis targets the joints and causes inflammation, 
and Parkinson’s disease also has a deleterious effect on function and health of 
the gut.  It appears that IBD can also be a result of a weakened immune system 
from other diseases with the gut becoming the ‘victim’ (Hvatum, 2006) 
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Inflammation can be found in other parts of the body such as arthritis in joints 
and uveitis an inflammation of the eye.  It is thought that these too are due to a 
fault in the immune system (From web page4).  
 
1.3 Sulphate-reducing bacteria and their potential to cause 
disease 
 
Anaerobic bacteria such as Clostridium difficile, for example, present in the 
colon, produce metabolites such as (H2S) which is extremely toxic as it inhibits 
butyrate oxidation and is implicated in the pathogenesis of UC (Roediger, et 
al.,1993).  Synthesis and degradation of sulphur containing molecules is 
mediated by the sulphur anion metabolic pathway which involves the enzymes 
rhodanase (RHOD) and thiol methyltransferase (TMT).  These enzymes are 
capable of removing H2S.  A study of patients with UC with impaired 
detoxification H2S suggested that they have lower levels of these enzymes, 
(Picton, et al.,2007).   
Sulphate in the form of sulphur dioxide is a preservative in many foodstuffs such 
as bread, beer, wine and cider. A diet rich in meat also produces faecal sulphides 
(Richardson, 1999).  With the presence of SRBs and a greater amount of sulphur 
products available, they will compete with methanogenic bacteria and outnumber 
them (Christl, et al., 1992). Patients with ulcerative colitis have shown to have 
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more SRBs and sulphide in the faeces than healthy individuals (Gibson, et al., 
1991).  Although the Wellcome study did not arrive at the same conclusion 
because sulphide complexes were not found to this extent from the UC patients.  
Some data is available for the absorption of the sulphate ion and a study of six 
healthy ileostomists and three normal subjects were chosen to measure 
absorption by addition of dietary sulphate.  Urine samples found that the normal 
subjects had 12% more bound sulphate than the ileostomists.  This is expected 
to have been derived from the metabolism of aromatic amino acids by gut 
bacteria.  The sulphate content in faeces was low even from volunteers fed with 
higher doses of dietary sulphate (Florin, et al., 1990). 
 In the last decade interest in SRBs and their significance in fermentation has 
become a focus for study; SRBs outcompete the MRBs in the gut.  A comparison 
between two populations showed that a population from the UK had a higher 
incidence of SRBs than rural South Africans.  Breath samples from the latter 
having a larger percentage of methane in breath compared to the UK population 
(Gibson, et al., 1988). 
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1.4 Characteristics for Inflammatory Bowel Disease 
 
1.4.1 Diseased gut 
 
  It appears that good hygiene and twentieth century life-styles are having a 
deleterious effect on the function of the human gut, incidence of IBD is higher in 
industrialized countries than in the third world.  Diet may be a significant factor.  
A pre-illness study found that sucrose, fat and refined carbohydrate intake was 
more common in CD and UC cases (Reif, et al.,1997).  
 The general terms for gastrointestinal disorders are structural or functional 
disorders.  Structural disorders include CD, UC where sulphumucins protecting 
the gut epithelium is removed causing it to become inflamed  and damaged, villi 
become worn down and absorption of nutrients is restricted (McFarland, 2008). 
Other disorders occurring in the GI tract are diseases such as diverticulitis, 
polyps and colon cancer (Morini, et al., 2008).  Functional disorders include IBS; 
the gut goes into spasm causing pain altering the progress of the gut contents.  A 
number of other inflammatory bowel diseases include infectious colitis, ischemic 
colitis and relatively newly discovered diseases such as eosinophilic oesophagitis 
(Attwood and Lamb, 2008).  
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1.4.2 Common Features 
 
CD, UC and IBS have similar symptoms ranging from abdominal pain, bloating to 
general discomfort.  Individuals have bouts of diarrhoea or constipation and 
generally feel quite unwell.  It is not until the patient is investigated for these 
symptoms that a diagnosis can be made to identify which of these three IBD 
categories it is. 
All conditions vary with intensity of physical symptoms and commonly found with 
one or a combination of inflammations of the lining of the intestine, bleeding and 
ulceration.   Disease cycles includes bouts of remission and then flare up again.  
Ages between 15 and 35 appear to be the most susceptible to onset of disease 
and all conditions tend to be life long and have to be managed either by 
medication, diet, or change in lifestyle.  The longer disease is present without 
intervention the greater damage occurs to the GI tract and surgery is required. 
Occasionally, disease is life threatening.  Diagnosis of these conditions requires 
very invasive and uncomfortable investigations such as barium enemas, 
sigmoidiscopy and colonoscopy.  Patients often resist going to the doctors due to 
the thought of these invasive procedures and may think they have something 
more serious.  
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Patients with IBD have more bacteria attached to the gut epithelium than do 
healthy people and this could be a key issue in causes to inflammation with 
regard to the reaction between the host and gut bacteria (Guarner and 
Malagelada, 2003). 
 
1.4.3 Crohn’s Disease 
 
 Crohn’s disease can affect any part of the digestive tract from the mouth to the 
rectum, but most commonly found by inflammation of the terminal ileum or small 
intestine and spreads through the whole wall of the intestine where mucosal 
lesions form over Peyer’s patches as shown in Figure 2.  Granulomas form from 
aggregated macrophages, giant cells and epithelioid cells which are surrounded 
by lymphoid, plasma and other inflammatory cells resulting in acute damage to 
the mucosa, with areas of inflammation patchy and segmental (Xavier and 
Podolsky  2007). One in 1500 people suffer from CD and it affects more women 
than men, and is most commonly present in young adults.  Diet may be a 
contributory factor as people diagnosed with Crohn’s disease often eat more 
sugar and fat than people without IBD (Hunter, 1998). 
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1.4.4 Ulcerative Colitis 
  
Ulcerative colitis is a chronic inflammation and affects the large intestine (the 
colon and rectum) rather than the entire gastrointestinal tract as is the case for 
CD.  About 1 in 1000 people develops UC in the UK; most tend to be young 
adults when disease is first apparent.  The cause is unknown and can run in 
families.  Although the condition is life long it has periods of remission.  When 
active, the patient has symptoms of abdominal pain, bouts of diarrhoea that often 
contain blood.   Stools and flatus have an unpleasant abnormal odour.  The 
patient may also be anaemic due to the loss of blood and will lose weight.  
Malaise and general lethargy are common features.  When a patient has a 
severe flare up, the whole colon can become ulcerated and it may perforate 
requiring surgery; this occurs in about 3 out of 10 patients.  People diagnosed 
with UC sometimes go on to develop colon cancer (Web page1).  
Inflammation of the gut wall is thought to be caused by the mucosal lining being 
damaged by enteric bacteria, either from a pathogenic source or from the normal 
commensal bacteria. Histopathological examination shows numbers of 
neutrophils found in the lamina propria and crypts (see Figure 2 ) causing 
ulceration to occur (Xavier and Podolsky, 2007). Patients with UC have been 
found to have SRBs with about 92% Desulfovibrio species present in faecal 
samples (Gibson, et al., 1991). 
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 The hosts’ own immune response can also be defective and inflammatory cells 
activate and damage the mucosal lining and/or lose tolerance to the normal 
enteric bacteria.  These autoimmune mechanisms occur from genetic 
abnormalities and trigger an autoimmune response of overly aggressive T-cells 
to enteric bacteria and cause damage to the mucosal lining (Sartor, 2006).   
Both CD and UC patients carry genetic disorders in the mechanism of regulation 
of inflammatory cells and cytokines are different from that in healthy people.  A 
number of genes such as the CARD 15 formerly known as the NOD 2 gene have 
been identified in patients with IBD that are linked with disease (Sartor, 2006). 
Experimental models, using rats and mice, to recreate the conditions of colitis to 
distinguish and show factors that contribute to disease and identification into the 
genes responsible have been studied (Elson, et al., 1996). 
Studies into the guts response to environmental triggers and stresses have 
shown enhanced gastrointestinal inflammation causing development of colitis 
conditions in rats (Gué, et al., 1997). 
 
1.4.5 Irritable Bowel Syndrome 
 
The symptoms of IBS are abdominal discomfort and pain, flatulence and bowel 
dysfunction and some IBS patients may also be genetically susceptible to 
inflammatory conditions (Collins, et al., 2001).  It appears to be a functional 
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disorder of the gut, often with no actual abnormality to the structure.  However,  
the muscular wall goes into spasm causing pain.   Persistent malfunction may 
then increase the chance of inflammation and ulceration.  IBS seems to present 
itself in three forms: diarrhoea-predominant (IBS-D), constipation-predominant 
(IBS-C) and alternating diarrhoea-constipation (IBS-A). The Rome III, Manning 
criteria has been developed to standardise the diagnosis of IBS (McFarland, 
2008).  It is not known what triggers the condition but there are several 
possibilities from food intolerance, altered bowel microflora, stress resulting in 
impaired mucosal blood flow, or induced by illness and/or emotional upset 
(Bowen, 2001).  
 
1.4.6 Investigation and Diagnosis of Disease 
 
Internal examination is performed to investigate and diagnose each condition and 
is often performed by a barium enema or a barium meal (depending on which 
part of the gut is affected) and X-ray; sigmoidoscopy, colonoscopy and/or a 
biopsy performed for histological examination, each of which is invasive and 
uncomfortable for the patient.  From initial onset of the disease to the first visit to 
the doctor and eventual referral for investigation it can take over a year to pass 
before a diagnosis can be confirmed and before treatment can start (McFarland, 
2008).  
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1.4.7 Medication and Treatment 
 
Treatment for CD and UC includes medication such as steroids, and 
immunosuppressant agents such as 6-mercaptopurine and azathioprine which 
help to reduce the inflammation.  Medication is not a cure and often has 
undesirable contra-indications and patients are usually on medication for life.  
Suppositories and enemas are also used as they treat the condition from the 
rectum upwards; however they are embarrassing and uncomfortable for the 
patient.  Surgery is performed if the conditions persist or become more serious; 
badly damaged parts of the gut are removed and patients then require a 
colostomy. Although this outcome has its unpleasant side, it is often life saving 
(Singleton, 2005). 
Finding the correct medication for IBS is somewhat more complicated than CD 
and UC as it covers a range of conditions.   Anti-diarrhoeal, anti-spasmodic or 
anti-depressants can be prescribed, hopefully tailored for individual cases.  
However, the choice of treatment can be somewhat ‘hit or miss’ and it can take a 
long time to find effective relief.  Surgery is usually not necessary for IBS, but 
invasive investigation such as endoscopy and colonoscopy are often carried out 
to eliminate the possibility of more serious illness as the disease presents itself in 
as similar way to CD or UC.  When other conditions are ruled out, IBS is 
tentatively diagnosed, not always a satisfactory conclusion for the patient as it 
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can be difficult to prescribe effective treatment for the causes of the symptoms.  
All conditions, once present, tend to be long term and have to be managed. 
 
1.4.8 Research into diagnosis and treatment 
 
 Novel techniques such as volatile analysis have been used to investigate 
disease from patients with IBD.  Breath samples were found to have raised levels 
of alkanes and this has been observed as an indication of excessive lipid 
oxidation, also a marker for ageing and inflammatory conditions (Salminen, et al., 
1998). 
Peroxidation causes damage to the intestinal epithelial barrier and allows 
bacterial antigens to enter the submucosal layers initiating impairment to the 
immune response, discovered in 2007 but the causality is still unknown (Rezaie, 
et al., 2007). 
Obtaining fluid samples during a colonoscopy examination  for VOC analysis for 
comparison with a breath sample from the patient was one approach as the 
patient was already undergoing examination, ‘colonoscopy-fluid’ was easily 
obtained without further invasive treatment .  Although the results were not 
altogether conclusive it did show that this may, with further work, have 
advantages as a diagnostic tool (Lechner and Rieder, 2007).  
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Individuals suffering from disease have been observed to have abnormal 
sulphurous smelling faeces; a cohort and longitudinal study was performed on 
faecal samples from healthy and diseased patients.  The study included patients 
with CD, UC; and patients with Clostridium difficile and Campylobacter jejuni 
infection.  Volatile compounds found for each condition were significantly 
different and manageable for statistical analysis to give clear differentiation 
between gastrointestinal diseases (Garner, et al., 2007). 
Examination of the thickness of the mucosal layer was undertaken by patients 
with CD and UC and appeared to have differences in the thickness from normal 
healthy gut and it was thought that colonic contents may be responsible for the 
damage to the mucosal layer (Pullan, et al., 1994).  Both CD and UC show a 
higher risk to colon cancer (Burstein and Fearon, 2008). 
Infection, antibiotics and non-steroidal anti inflammatory drugs implicated in 
causing inflammation by altering the mucosal barrier and the immune response, 
although the mechanisms that initiate conditions are not fully understood (Elson, 
et al., 2003). 
A persistent pathogen infection of Mycobacterium avium subspecies 
paratuberculosis (MAP) which is found in pasturised cow’s milk may cause 
development of CD (Ayele, et al., 2004). 
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1.5 Benefit of breath testing to the Healthcare Service 
 
Globally, visits to healthcare services have increase for people with symptoms of 
IBD.  In the United States, 30,000 new cases are diagnosed every year and up to 
15 million adults suffer with IBS.  In the UK 10 to 15% of the adult population are 
affected by IBS.  Due to the chronic nature of this illness reinvestigation and 
further treatment is often required; becoming costly to both patient and health 
care provider (Bassi, et al., 2004).  Identification of VOC biomarkers and using 
them in a portable device, or a version of the SIFT-MS that is cheaper and small 
enough for monitoring and diagnosis of disease would provide a rapid, reliable 
low cost method that could be used in a hospital out patients without the need of 
trained staff (Turner, et al., 2006).   
 
1.6 Other Research into IBD with the Wellcome project and other 
establishments 
 
Identification and characterisation of SRBs, to determine disease-specificity; and 
genomic screening to establish polymorphism in genomic DNA was part of the 
Wellcome project at the University of Birmingham.  
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The Gastroenterology Unit at Addenbrooke’s Hospital, Cambridge is run by 
Professor John Hunter who is the honorary consultant physician and currently 
leads an active research team carrying out studies of the gut microflora and 
inflammatory bowel conditions. 
 HFL Sport Science Quotient Bioresearch Ltd at Fordham in Cambridgeshire 
funded analysis of the Wellcome urine samples analysis by Liquid 
Chromatography Mass Spectrometry initially for sulphur compounds.   
University Hospital South Manchester, Department of Medicine, run by Peter 
Whorwell who is Professor of Medicine and Gastroenterology, has a particular 
interest in functional disorders of the gut and has written many papers on the 
subject.  One of which concerns the risk of damage to the pelvic floor from 
constipation (Amselem, et al., 2009).  
The University of the West of England and Bristol University have worked 
together to find a rapid diagnosis method for identification of the chemical 
composition of faeces for a number of conditions including Clostridium difficile 
infection in the gut, run by Professor Norman Ratcliffe and Dr Chris Probert. 
The MRC Mitochondrial Biology Unit formerly known as the Dunn Human 
Nutrition Unit in Cambridge has done extensive research on IBD (Gibson, 
Cummings and Macfarlane, 1993). 
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1.7 Susceptibility for IBD in other countries 
 
IBD research shows Chinese people appear to have a lower incidence than 
Western populations for susceptibility (Singleton, 2005) and may be due to 
genetic differences between populations or differences in diet and lifestyle.  
People living in the tropics and the Indian subcontinent may have more microbes 
in the small intestine (Cummings and Macfarlane, 1991).   Gastrointestinal 
disease has become more prevalent and is more common in the Western World 
than developing countries.   
CD affects, proportionally, more people in Wales, New Zealand, Canada, 
Scotland, France, The Netherlands and Scandinavia, than the rest of the World. 
IBD is lower is Brazil, China, Korea, Greece, Japan, Malta and Slovakia 
(McFarland, 2008). 
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1.8 VOCs and diagnosis 
 
VOCs have a potential as marker compounds from normal health to many 
disease situations.  They arise from various sources.  For example, as normal 
metabolic compounds produced from physiological processes and from 
compounds produced from bacteria which are either pathogenic or commensal.  
Gastro enteric bacteria are very numerous and varied, producing a large number 
of volatiles from their metabolism.  When IBD is present the balance of good to 
bad bacteria becomes altered and volatiles produced may be useful indicators of 
gastrointestinal dysfunction. The host body also produces VOCs as a response 
to infection occurring from immunoregulation when an inflammatory response is 
triggered.   
 
1.8.1 Breath as a medium for health monitoring 
 
Using VOCs in breath to investigate and monitor a range of diseases could 
replace more invasive methods presently used in surgeries and hospitals, such 
as from blood or biopsy samples.  A non-invasive method of breath analysis is 
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quick and painless and acceptable to children and elderly alike.  The rapid time 
response of such a device for monitoring and diagnosis of disease would be 
more favourable than using blood and even urine and faeces as, although rapid 
tests are available, it can take up to a week for diagnosis.  Costs would also be 
lowered for a technique where laboratory staff would not be required extensively 
for regular clinical testing.  An instrument like the SIFT-MS but smaller and less 
costly to run and with a one step monitoring and testing application would be of 
great use in a hospital clinic (Smith and Španĕl, 2010).   
 
1.8.2 Limitations of breath for disease monitoring – other clinical matrices 
as providers for VOC biomarkers  
 
 Many compounds found in breath originate from blood; they pass across the 
blood/alveolar barrier from the lungs into breath (Van de Velde, et al., 2008).  
Urine too, contains many compounds that are found in blood these pass through 
from blood into the kidneys by renal filtration.  Although not as straight forward as 
a breath sample it is still a useful ‘medium’ for extracting information from what is 
occurring within the body as it is non-invasive. Faecal samples give a ‘coal face’ 
analysis to what is happening, especially where gut disease is apparent, from 
within the lumen and luminal contents to provide information of bacterial balance 
and activity within the gut, but not the most suitable sample type to use for 
regular diagnostic testing, and patients do not like providing stool samples.  
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Storage and handling of these liquid and solid clinical samples also have a time 
and cost implication.   
Breath simply by its ease of capture has many potential benefits but it also has 
disadvantages.  Compounds present in breath are not always endogenous or 
systemic and become contaminated by metabolites present in mouth bacteria 
from the oral cavity.  Mouth and nose-exhaled breath have been compared and 
shows that nose sampling would be preferred (Smith and Španĕl, 2010).  Breath 
also contains many exogenous compounds absorbed by the body from the 
environment. For example, xylene found in paint and substances such as 
benzene, trihalomethane, and many others from occupational exposure.   
Monitoring people to exposure of chemicals is another area where breath 
analysis can be of use, but this might compromise the effectiveness of using 
breath as contamination may interfere with the trace compounds of interest (Di 
Francesco,et al., 2004). 
 
1.8.3 History and research diseases using breath analysis 
 
Odour  has been used to identify disease for thousands of years; the Greek 
physician Hippocrates knew that human breath may provide clues to poor health 
due to characteristic odours; some were recognised as indicators for disease 
such as the fruity smell of acetone for diabetes.  We have since discovered that 
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VOCs found in breath and body fluids may be used as markers for disease.  
Breath VOC identification has been extensively researched but less literature has 
been found for VOCs from blood, urine and faeces.   
During the 1970’s Pauling et al detected more than 200 compounds in human 
breath with the use of gas chromatography.  Antony Manolis, working in the 
same area discovered 200 compounds in breath of healthy subjects but at the 
time in 1983 did not know which metabolic pathways produced those (Manolis, 
1983) and many are still not known.  Separation of compounds and accurate 
identification became more reliable in the 1980s and 1990s with the progress of 
analytical methods (Miekisch, et al., 2004).  During the 1990s identification of 
breath components in cross-sectional and longitudinal studies investigated 
exhaled biomarkers for assessment as predictive markers for disease (Cao and 
Duan, 2006).  Latterly, GC-MS and more recently SIFT-MS which is capable of 
measuring several compounds simultaneously, can analyse VOCs from exhaled 
air, within a few seconds (Smith and Španĕl, 2010).  It has a potential as a tool 
for non-invasive disease diagnosis, and the advantage that it can be used for real 
time, on line breath sampling for a variety of diseases with identification of 
compounds down to parts per billion (Turner, et al., 2006). 
 
A study of patients with cystic fibrosis and asthma found elevated levels of 
hydrogen cyanide (HCN) in breath from Pseudomonas aeruginosa infection in 
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children with cystic fibrosis and conversely those with asthma had lower levels of 
HCN but higher levels of nitric oxide (NO) in their breath (Smith and Španĕl, 
2010). 
Breath screening was used for patients diagnosed with type 2 diabetes with 
samples being collected into Tedlar bags for GC-MS analysis.  Findings showed 
acetone levels elevated in people with diabetes (Da Silva et al., 2008). VOCs 
such as aromatic hydrocarbons from breath samples have been found in higher 
concentrations for patients with lung cancer (Poli, et al., 2008). Patients with 
congestive heart failure (CHF) have been shown to have breath acetone levels 
four times higher than control subjects (Kupari, et al., 1995).  
Breath contains a number of alkanes such as ethane and pentane found to be 
markers for oxidative stress and present when disease is active (Aghdassi and 
Allard, 2000). Pro-inflammatory cells and bacteria produce oxidised compounds 
from metabolism.  Isoprene in breath is implicated in cholesterol metabolism and 
organ failure (Kuzma, et al., 1995).  
  
1.8.4 Headspace Analysis – for clinical matrices  
 
A gas sampling technique known as headspace analysis was used for clinical 
samples.  Liquid or solid sample forms equilibrium within a headspace over the 
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sample matrix, contained and isolated from the ambient environment inside a 
sample bag.  The equilibrium theory was proved by William Henry in 1803 and 
his law (Henry’s Law) states that, (Pysanenko, et al., 2009). 
 ‘At a constant temperature, the amount of a given gas dissolved in a given type 
and volume of liquid is directly proportional to the partial pressure of that gas in 
equilibrium with that liquid’  
VOC analysis using methods to obtain a representative sample of volatile 
compounds from liquids and solids was a novel technique in the late 1990s; and 
a method to trap the gas phase in equilibrium with a liquid or solid was developed 
in 1996 for a number of applications (Creasy and Capuano, 1996).  This 
technique also known as headspace analysis is used with SIFT-MS and ATD-
GC-MS.  Since then headspace analysis has been used for a variety of 
applications including volatile fractions from cows’ milk analysed by this novel 
technique (Toso, et al., 2002), and urinary headspace with SIFT-MS (Abbott, et 
al., 2003). 
 
1.9 Analytical Techniques for VOCs in breath and clinical 
matrices 
 
1.9.1 Collection of breath samples 
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A Breathotron device was used at Addenbrooke’s Hospital to collect breath and 
ambient air samples. Direct breath samples were taken from patients in a matter 
of minutes via a facemask as shown in Figure 4 where breath is passed onto a 
TD tube containing Tenax® for analysis by GC-MS.  
 
Figure 4 Particle mask (3M model no 750) adapted with tube for attachment 
to Breathotron  
 
1.9.2 Gas chromatography – Mass spectrometry 
 
Tube for attachment to 
Breathotron 
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GC-MS is an important analytical method for the analysis of VOCs, it is semi-
quantitative and very sensitive for the determination of individual substances in 
complex mixtures down to ppb/ppt.  The sample in its gaseous phase is passed 
onto a column by carrier gas, usually helium, where the separated components 
elute from the column at different times, then each is analysed by the mass 
spectrometer where components are broken into ionised fragments and detected 
by their mass to charge ratio (m/z).  The fragments are compared with stored 
libraries of compounds for identification.    
 
Figure 5 Cranfield Health Department ATD GC-MS System 
 
Automatic thermal desorption (ATD) with GC-MS (and apparatus shown inFigure 
5) is a standard technique for the analysis of VOCs especially non polar analytes 
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with low molecular weight.   Thermal desorption tubes containing adsorbent 
materials such as Tenax® and Carbotrap® are used to trap VOCs passed from a 
headspace containing a liquid or solid or breath sample.  The headspace sample 
was passed onto the tube through a flow pump and the breath sample passed 
onto the TD tube via the Breathotron device.  This technique was useful for pre-
concentration of sample so that trace compounds at ppt concentrations could be 
detected (Knobloch, 2009), and for transport and storage prior to analysis.   
GC-MS does although have some disadvantages.  Water vapour can provide 
erroneous results and has to be removed prior to analysis.  It is very expensive to 
perform sample analysis and the equipment is not portable, although samples 
are collected on the TD tubes. The analysis time is slow and only semi-
quantitative compared with the SIFT-MS.   
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Figure 6 TD tubes showing permanent and temporary caps 
 
Figure 6 shows two TD tubes, the upper one with permanent brass end caps; 
these caps are in place while tubes are being stored or in transit.  The white 
PTFE temporary caps are used while the tubes are on the ATD. The actual size 
of TD tube is 9cm long. 
 
 
 
 
 
TD tube with brass end caps 
TD tube with PTFE caps 
Scribed numbers on tube for 
identification 
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Figure 7 Schematic of the GC-MS showing different components and 
processes from desorption to the TIC 
 
 
1.9.3 Selected ion flow tube – mass spectroscopy 
 
The SIFT-MS, shown in Figure  is a Model Profile 3, manufactured by Instrument 
Science Ltd, (Crewe, Cheshire); it is being developed as a method of analysing 
breath from patients; and determines on-line real-time measurements of volatile 
compounds down to ppb (Smith, Španĕl 2005).  The capabilities of breath 
analysis by this technique once established have many advantages (Miekisch 
and Schubert, 2006).  Non-invasive breath testing for these conditions is much 
less embarrassing for patients than existing diagnostic tests and may encourage 
people with symptoms to seek help leading to faster treatment.  The high 
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moisture content of a breath is well tolerated by this method producing 
quantitative analysis of many compounds.  
 
 
 
 
 
 
Figure 8 Diagram of the SIFT-MS 
 
 Breath and headspace samples pass through a heated capillary and into the 
flow tube where three precursor ions; H3O
+, NO+ and O2
+  are generated from the 
upstream injection quadrupole (see Figure 8) used to ionize the trace gases in 
the sample. The precursor ions and product ions are then carried down the flow 
tube by helium onto detection quadrupole mass spectrometer and the ions are 
counted by the mass detector producing a mass spectrum.  Two modes of 
operation are used; the full scan mode which is semi-quantitative where the ions 
are analysed over a selected mass range, and secondly a quantitative multiple 
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ion monitoring mode in which individual ions are selected for monitoring (Turner, 
et al., 2006).  
 
Figure 9 SIFT-MS with incubator and laptop  
 
Figure 9 shows the SIFT-MS used in this study.  Development of the SIFT-MS, or 
a similar device, such as Proton Transfer Reaction Mass Spectrometry (PTR-
MS) measures VOCs in real time and produces mass spectra within seconds, is 
much quicker than GC-MS analysis.  
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1.10 Aim 
 
The aim of this project was to determine whether VOC markers could be found 
from breath, blood, urine and faeces and distinguish between CD, UC, IBS and 
healthy volunteers.  VOC markers have a potential to be used as a rapid 
diagnostic test for monitoring and identification of IBD conditions. 
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Chapter 2 
 
 
2.1 Materials and Methods 
 
2.1.1 Patient Recruitment and sample collection 
  
A total of 91 volunteers recruited from the Gastroenterology department at 
Addenbrooke’s Hospital in Cambridge provided samples for this study to produce 
the data required for analysis.   From the volunteers 24 were diagnosed with CD, 
19 with UC and 28 with IBS and 20 healthy volunteers were used as controls.   
When the volunteers had verbally agreed to donate samples they were given a 
letter explaining why the trial was being conducted and what they would need to 
do.  
Patient confidentiality was required for data protection and each volunteer was 
given a unique code number that was attached to each of their sample 
containers; this also enabled the samples to be analysed blind which was a 
prerequisite for the trial.   Addenbrooke’s is the keeper of the patient list and 
cross reference to the unique codes which identifies disease conditions.  This 
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was not released to the project partners, Cranfield, until patient recruitment and 
sampling was complete to ensure that the study was carried out blind. 
All volunteer recruits were given a consent form to sign and asked to fill in a 
questionnaire for details on diet, sleep, exercise, alcohol and nicotine intake, 
medication and general health.  Samples were taken as soon as possible after 
consent was given the date and time of this was filled out on the consent forms. 
Breath, urine and blood samples were taken from each volunteer.  Sample pots 
were provided for faecal samples to fill at the next opportunity for patients and 
then handed in for storage, prior to analysis.  The samples were stored at 
Addenbrooke’s, frozen at -40˚C until they were collected for delivery to the 
University of Birmingham and Cranfield University.  At Cranfield the samples 
were stored at -80˚C prior to analysis.   Freezing the samples inhibits 
biochemical and bacterial processes from occurring.  Vapour emissions from 
human urine samples were not significantly changed by freezing, for samples 
analysed by GC-MS and SIFT-MS (Peakman and Elliot, 2008).  
Patients with disease conditions were asked to supply a second batch of 
samples after they had received treatment.  The protocol for sample collection 
was the same as for the first set of samples. 
Ethical consent was given for this Wellcome Project by the National Research 
Ethics Service.  Human Tissue Sample Record Sheets (HTRS) were kept for 
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blood, urine and faecal samples.  The reference numbers were added to the 
HTRS when samples were collected from patients.  The date was entered when 
the sample was analysed, and finally a date was entered when the sample was 
destroyed in accordance with instructions for the protocol for ethical consent.  
Information of age and gender was sent to Cranfield towards the latter part of the 
study and was analysed to show trends.  
 
2.1.2 Breath Sampling – Breathotron and TD sample collection 
 
The volunteer was given the opportunity to relax before sampling started, 
subsequently they were given a standard 3M mask; Model no. 750 to wear, that 
was modified with a PTFE tubing arranged to carry the breath to the Breathotron.  
The patient was asked to breathe normally, for about five minutes until a volume 
of 500ml had passed across the TD tube.  
 The mask was generally well tolerated by patients they were asked to relax and 
breathe normally while the breath sample was being collected.  MMOS sensor 
data were stored on a PDA attached to the Breathotron.  These data were 
collected for the Wellcome study but was not required for the Masters project.  
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Breath compounds were collected onto a TD tube containing 50% Tenax TA and 
50% Carbotrap (Markes International Ltd, Llantrisant, UK) via the Breathotron. 
 
  
 
2.1.3 Breath – Bag Samples 
 
Breath samples were collected into pre-prepared breath sample bags.   The 
prepared bags were manufactured from a metre strip of ‘Nalophan NA’ (polyethylene 
terephthalate) purchased from Kalle GMbH & Co. KG. Rheingaustrabe, 190-196 D-
65203, Wiesbaden, Germany, with a 70mm length of polypropylene tube and a 
Swagelok closure fitted into the apical opening.  The Nalophan NA was carefully fan 
folded to wrap around the tube and then tied with two tie-wraps to secure the tubing; 
the basal end was also fan folded and then approximately two centimetres was 
folded over and secured with two tie-wraps, this made an adequately air tight 
container.  Patients were asked to relax and then breathe normally into the bag 
through the uncapped Swagelok closure until it was full and then closure screwed 
tightly shut.  Breath bags were labelled with unique patient ID number. 
The breath bags and TD tubes were then despatched to Cranfield via courier and 
breath bags were analysed by SIFT-MS upon arrival.  TD tubes were refrigerated at 
4°C prior to analysis with GC-MS. 
 
2.1.4 Headspace Analysis 
 
Bags for the liquid and solid clinical samples were prepared from slightly smaller  
Nalophan NA tubing than the breath bags.  These were prepared from 100mm wide 
Nalophan NA cut to 500mm lengths, and similar to the breath bags with a Swagelok 
fitting with tube attached to the apical end with tie wraps and the basal end was left 
open for the sample to be added.  When the bag was sealed and zero grade air 
Sealed Swagelok 
fitting 
Identification number 
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added this created an environment for a headspace above the sample for VOCs to 
be released from the liquid or solid phase (Figure 10).   
 
 
 
 
 
 
 
 
Figure 10 Headspace bag containing a blood sample and filled with zero grade 
air.  
 
The blood, urine and faecal sample aliquots were transferred into a bag. The actual 
amount of sample placed into each bag was not critical.  All blood, urine and faecal 
samples required thawing from -80°C to room temperature before preparation.  An 
aliquot of blood was dispensed by pipetter into the open, basal end of the Nalophan 
bag which was then folded and tie-wrap sealed.  The bag was then attached to line 
with zero grade air via the Swagelok fitting and filled with sufficient air to make it 
rigid.  A similar aliquot of urine was placed into the Nalophan bag or approximately a 
3g ‘splodge’ of faeces placed into the bag. The following procedure was then the 
same for the urine and faecal samples.  The bag was labelled with the corresponding 
patient Wellcome number and then placed in an incubator at 40°C for 10 minutes to 
Closed Swagelok fitting 
on the apical end 
Label for 
identification 
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allow the headspace to equilibrate.  A bag filled with zero grade air and without 
sample was used as a blank.  Table 14 in the appendix shows list of compounds. 
 
2.2 Analytical Methodology 
 
2.2.1 Capture of volatiles onto TD tube from headspace 
 
Liquid and solid clinical samples: - Headspace from urine, blood and faecal samples 
was drawn from the bag by using a FLEC® constant-flow pump purchased from 
Markes International, Llantrisant, Wales using a flow rate of 100ml for 5 minutes and 
passed onto a TD tube.  The tube was then stored at 4°C prior to GC-MS analysis. 
Breath samples:- The breath TD tube samples, on arrival at Cranfield, were checked 
to make sure TD tube number inscribed on the tube and patient Wellcome number 
corresponded to the record sheet included then stored at 4°C until a batch of 
approximately 50 TD tubes was ready for a run on the GC-MS.  Standard operating 
procedure (SOP) for the preparation of the TD tubes for addition of standard and 
GC-MS analysis is described in the Appendix 5.4. 
 
2.2.2 GC-MS Instrument Settings and Conditions 
 
A Perkin Elmer system was used for volatile analysis, combining a TurboMass MS 
4.1(Software version), Autosystem XL GC and Automatic Thermal Desorption 
system ATD 400 (Perkin Elmer, Wellesley, MA).  The carrier gas was CP grade 
helium (BOC gases, Guildford, UK) passed through a combined trap for removal of 
Dawn Fowler 
MSc by Research 
‘Analysis of volatile marker compounds in body fluid samples from patients with gastrointestinal 
disease' 
 
46 
 
hydrocarbons, oxygen and water vapour.  The trap was changed after every fourth 
helium cylinder.  A wall-coated Zebron XB624 chromatographic column was used 
(Phenomenex, Torrance, CA), with dimensions 30m x 0.4mm x 0.25mm (internal 
diameter), the liquid phase comprising of a 0.25µm layer of 6% cyanopropylphenyl 
and 94% methylpolysiloxane.  
TD tubes were desorbed by purging for 2 min at ambient temperature then for 5 min 
at 300°C.  Volatiles purged from the TD tubes were captured on a cold trap which 
was initially maintained at 30°C.  The ATD valve was set to 180°C and TD tubes 
were desorbed onto the secondary cold trap which was initially maintained at 30°C.  
This purges the tubes to remove water and other contaminants. Once desorption 
was complete, the trap was heated to 320°C using the fastest heating rate and then 
maintained for 5 min whilst the effluent was transferred to the GC via a transfer line 
heated to 210°C.  The GC oven was maintained at 50°C for 4 min after injection and 
then raised at increments of 10°C per minute until reaching 220°C and then held for 
9 min.  The eluted products were transferred by a heated line held at 240°C to the 
MS where the compounds were ionised to carry out a full scan of mass/charge ratios 
from 33 to 350m/z with a scan time of 0.3s and 0.1s delay producing mass spectra 
with a total ion chromatogram (TIC).  
 
2.3 Compound Identification     
 
Compounds were identified by Automated Mass spectral Deconvolution and 
Identification System (AMDIS) Version 2.62, allowing identification of target 
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compounds from raw GCMS data by comparing with the mass spectral library from 
the National Institute of Standards and Technology (NIST).  A representative part of 
all the compounds deconvoluted from each clinical sample was copied onto an Excel 
spreadsheet as shown on Table 1.  The NIST library, Version 2.0c, was used to 
compare with the AMDIS identification for the best of the three retention time 
matches and shown in Table 2.  The first one from each three with the same 
retention time.  This was then used to process the data and was a much quicker 
method than checking all three matches with the same retention time with the NIST 
library to make a choice.   
Table 1 AMDIS data showing sample of set compounds found (Name) with 
retention time for that compound (R.T.) and Amount in %.  Table 2 is 
representative of a full list of several hundred compounds. 
Name R.T. (minutes) Amount 
argon 3.88 0.13% 
propyne 3.88 0.13% 
borane carbonyl 3.88 0.13% 
nitrous Oxide 4.011 1.40% 
carbon dioxide 4.011 1.40% 
phenol, 4-[2-
(methylamino)ethyl]- 4.011 1.40% 
sulfur dioxide 4.569 0.54% 
aminomethanesulfonic acid 4.569 0.54% 
2-aminoethyl hydrogen sulfate 4.569 0.54% 
ethylene oxide 4.781 1.41% 
alanine 4.781 1.41% 
cyclopropyl carbinol 4.781 1.41% 
1-propene, 2-methyl- 4.94 0.09% 
1-butene 4.94 0.09% 
cyclobutane 4.94 0.09% 
acetaldehyde 5.236 1.56% 
formic acid, ethenyl ester 5.236 1.56% 
ethylene oxide 5.236 1.56% 
hydroxyurea 5.414 5.07% 
DL-cystine 5.414 5.07% 
cystine 5.414 5.07% 
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butane, 2-methyl- 5.92 0.11% 
pentane 5.92 0.11% 
isobutane 5.92 0.11% 
trichloromonofluoromethane 6.288 0.18% 
2,4-dioxabicyclo[3.2.0]hept-6-
en-3-one, 1,5-dichloro-6,7-
dimethyl- 6.288 0.18% 
phosphorus trichloride 6.288 0.18% 
trichloromonofluoromethane 6.292 0.38% 
2,4-dioxabicyclo[3.2.0]hept-6-
en-3-one, 1,5-dichloro-6,7-
dimethyl- 6.292 0.38% 
phosphorus trichloride 6.292 0.38% 
pentane 6.362 0.64% 
isobutane 6.362 0.64% 
butane, 2-methyl- 6.362 0.64% 
pentane 6.3623 0.64% 
ethyl alcohol 6.541 1.92% 
hydrazine, methyl- 6.541 1.92% 
methane, nitroso- 6.541 1.92% 
trimethylene oxide 7.114 0.02% 
 
 
Table 2 Amdis data again showing first choice from R.T. The additional column 
is the Absolute amount calculated from the Absolute Amount of Toluene-D8 
(ng/l). 
Name R.T. (minutes) Amount 
Absolute 
Amount 
ng/l 
acetaldehyde 5.236 1.56% 42 
hydroxyurea 5.414 5.07% 137 
butane, 2-methyl- 5.92 0.11% 3 
trichloromonofluoromethane 6.288 0.18% 5 
trichloromonofluoromethane 6.292 0.38% 10 
pentane 6.362 0.64% 17 
pentane 6.3623 0.64% 17 
ethyl alcohol 6.541 1.92% 52 
acetone 7.259 4.45% 120 
dimethyl sulfide 7.401 3.02% 82 
acetic acid, hydrazide 7.747 0.29% 8 
cyclopropane, ethyl- 8.095 17.50% 473 
butane, 2-methyl- 8.683 0.10% 3 
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butane, 2-methyl- 8.688 0.10% 3 
1-propanol 9.083 0.49% 13 
2,3-butanedione 9.661 0.60% 16 
2-butanone 9.897 0.62% 17 
methanesulfonyl chloride 9.936 0.15% 4 
2-butanol 10.08 0.15% 4 
1,3-dioxolane, 2-methyl- 10.919 0.12% 3 
isobutane 10.942 0.19% 5 
acetic acid 11.177 1.00% 27 
benzene 11.283 0.24% 7 
propane 11.423 0.28% 7 
1-butanol 11.953 0.32% 9 
propanoic acid 13.655 0.34% 9 
disulfide, dimethyl 13.896 2.62% 71 
toluene-D8 14.109 3.70% 100 
cyclobutene, 2-propenylidene- 14.219 0.14% 4 
butanoic acid, ethyl ester 14.675 0.02% 1 
ether, 2-chloro-1-propyl 
isopropyl 15.062 0.15% 4 
butanoic acid 15.79 0.60% 16 
butanoic acid, 3-methyl- 17.056 0.09% 2 
1,4-methano-1H-
cyclopropa[d]pyridazine, 
4,4a,5,5a-tetrahydro-6,6-
dimethyl-, (1à,4à,4aà,5aà)- 19.035 0.09% 2 
dimethyl trisulfide 19.811 0.17% 5 
benzaldehyde 19.918 0.19% 5 
1,7-octadiene, 3-methylene- 20.143 0.19% 5 
phenol 21.065 0.25% 7 
 
 
2.3.1 Biomarker Selection 
 
Hundreds of different compounds were produced from analysis from each of the 
clinical matrices.  An approach to find a manageable number of compounds for data 
handling that was not time consuming was required.  The faecal samples were 
chosen first as they had an abundance of compounds and seemed more likely to be 
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associated with disease.  Three batches of four GC-MS chromatograms with control, 
pre-treatment CD, UC and IBS were displayed together to enable a visual 
comparison.  Differences in compound peak heights from the chromatograms were 
compared with the AMDIS deconvolution list with the corresponding retention time 
(see Table 2).  Compounds with peaks showing a difference from controls and 
disease groups were chosen to go onto a short-list.  The list in Table 3  was then 
drawn up of compounds from which the short-list selection was made.   
Scoring for Table 3 was made by 0 being no peak visible and 3 being the greatest 
peak size. A total possible score was 9; for example 3 for the highest peak, times 3 
for the frequency that compound was seen in each of the three batches.  Figure 11 
shows the four GC-MS chromatograms the upper one is a pre treatment CD sample, 
then UC, IBS and a control sample providing a good method to visually compare 
chromatograms. 
 
p- 
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Figure 11 TIC alignment for control and pre treatment disease groups, some of 
the compounds have been highlighted where differences were found. 
 
 
Table 3 List of compounds selected from the visual inspection method for 
Candidate Compounds.  Peak height being given a score from 0 to 3 and this 
was multiplied by the frequency that compound from the three groups. 
Faecal samples - Candidate Compounds abundance     
Compound 
R.T. 
(minutes) Control 
Pre 
UC 
Pre 
CD 
Pre 
IBS 
trimethylamine 5.729 0 1 0 0 
ethyl alcohol 6.522 2 1 4 4 
acetone 7.24 3 7 4 6 
1-propanol 9.076 1 3 8 3 
propan-2-ol 7.42 1 1 2 2 
2,3-butanedione 9.672 1 2 2 1 
2 butanone 9.914 2 3 4 3 
acetic acid 11.167 1 5 3 5 
ethyl acetate 9.944 0 0 2 0 
acetonitrile 7.674 0 1 0 0 
1-butanol 11.976 1 2 5 5 
2 butanol ® 10.117 1 0 1 1 
2-pentanone/2,3-pentanedione 12.422 0 1 1 1 
      
methyl propionate 10.461 0 0 1 1 
1,3-dioxolane, 2-methyl/1-propanol, 2-methyl 10.962 1 2 2 2 
propanoic acid 13.825 3 2 5 6 
propanoic acid ethyl ester 12.518 0 1 4 0 
propanoic acid , 2-methyl 15.159 2 6 6 5 
butanoic acid 15.966 3 9 6 6 
n-propyl acetate 12.709 0 0 2 1 
butanal, 2-methyl 11.642 1 2 2 1 
hexane 11.6835 0 1 1 1 
disulfide, dimethyl 13.961 3 4 3 1 
butanoic acid, methyl ester 12.929 0 0 1 2 
butanoic acid, ethyl ester 14.911 0 0 2 1 
butanoic acid, 2-methyl ester 17.321 0 0 1 0 
butanoic acid, 3-methyl ester 17.157 0 0 1 0 
butanoic acid, 2 methyl 17.315 2 5 3 3 
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butanoic acid, 3-methyl  17.137 2 6 5 4 
styrene 17.581 0 0 1 1 
formic acid 13.816 0 2 1 1 
pentanoic acid 18.052 1 6 3 4 
2-propanol, 1-butoxyl  18.624 3 0 2 2 
propanoic acid, 2-methyl, butyl ester 19.402 0 1 0 0 
hexanoic acid 20.107 0 4 1 1 
5-hepten-2-one, 6-methyl 19.741 0 0 0 3 
dimethyl trisulfide 19.858 1 1 0 2 
phenol 21.122 2 1 3 4 
phenol, 4-methyl 22.919 4 0 5 5 
indole 29.546 3 6 8 6 
 
 
2.3.2 Candidate Compounds – short list 
 
The list on Table 3 gave the initial choice for further selection criteria based on three 
key ideas; 
 The ‘most abundant’ was selected from the list in Table 3.  Then going 
back to the Table 2 list which shows the ‘amount’ column abundance 
was then identified and ones with the most abundance chosen. 
 The ‘literature sourced’ were compounds sourced from the literature.  
For example, likely metabolites, which come from the host or bacteria 
resident in the gut.  Acetone is produced by lipolysis (Turner, 2006).  
Aliphatic acids can inhibit growth of gut bacteria. Carboxylic and short 
chain fatty acids such as propanoic and butanoic acid are produced by 
anaerobic fermentation of undigested carbohydrates by colonic 
bacteria. Intestinal mucosa is a major site for fatty acid ethyl ester 
synthesis and they may be involved in organ injury.  Methanol as a 
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product from MRB can become trapped as an ester by gut flora and 
thought to have health implications (Garner, et al., 2007).  Phenolic 
compounds such as indole, p-cresol and phenol are markers for protein 
fermentation (De Preter et al., 2009).  A total of 13 Candidate 
Compounds was chosen and Table 4 shows them with their 
corresponding GC-MS retention time. 
 Visual inspection, these were chosen from the list in Table 3 as ones 
with a difference between control and pre treatment disease groups. 
Table 4 Candidate compound Short –list in the groups of choice showing 
retention times for identification. 
Group Compound Retention Time (minutes) 
Most abundant acetone 7.24 
 propanoic acid 13.64 
 butanoic acid 15.84 
Literature sourced 1-propanol 9.083 
 propanoic acid, ethyl ester 12.47 
 butanoic acid, methyl ester 12.88 
 butanoic acid, ethyl ester 14.88 
 p-cresol 22.92 
 indole 29.59 
 disulpide dimethyl 13.89 
Visual inspection 1-butanol 11.97 
 butanoic acid, 3-methyl 17.12 
 phenol 21.12 
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2.3.3 Calculations of sample for semi-quantitative measurements 
 
An internal standard of D8 toluene was used for quantification.  Calculation and 
parameters used are shown below.  
Absolute amounts of Faecal Candidate Compounds were calculated from: 
Absolute amount = % of sample / % of D8 toluene x volume of standard, nano 
grams(ng) x dilution of sample, litre (l).  
Absolute amount = ng/l 
Volume of standard =50ng*1 
Dilution of sample = 0.5 litre*2 
% of sample and D8 Toluene was the value given in the ‘Amount’ column 
*1 Volume of standard dispensed by Hamilton syringe into the TD tube for 20seconds 
with a flow rate of 500mls/min. 
*2 100 ml/minute for 5 minutes 
 
2.3.4 Data Collection for Candidate Compounds 
 
Data for the 13 candidate compounds short-list in Table 4 was gathered from faeces 
for control and the pre and post treatment groups.  The same candidate compounds 
were looked for in blood, urine and breath.   
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2.3.5 Statistical Analysis 
 
Box and Whisker plots were a good method to visually compare the skewedness of 
the data.  Then non-parametric Kruskal Wallis test done to find significant differences 
between groups and the Mann Whitney U-test was used as a Post hoc test to 
determine differences between pairs within the groups where Kruskal Wallis test was 
significant (control and pre diseases groups), there were six pairs to compare 
candidate compounds; Control vs. CD, Control vs. UC, Control vs. IBS, CD vs. UC, 
CD vs. IBS and UC vs. IBS.  
 
2.3.6 Limit of detection for Candidate Compounds 
 
Two of the compounds from the candidate compound list were used for quantitative 
analysis to produce calibration curves and determination of the LOD.   
 
2.4 Method Development 
 
The GC-MS method used predominantly in this study was a general screening 
method for volatile analysis and was based on screening for as many compounds as 
possible for identification.  The general method provided the basis for compound 
identification and from the compiled short-list.  From the short-list two compounds 
were chosen for use in method development to improve a number of parameters; 
faster analysis time, better quantification, improve peak separation and to determine 
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the limit of detection.  The compounds chosen to use with method development were 
ethyl propionate and methyl butyrate, pure samples purchased from Sigma-Aldrich.  
They were chosen as their performance in the general method was having similar 
retention times and both eluted at mid-point in the analysis run time.   
 
2.4.1 Apparatus and method modification 
   
Apparatus modifications: 
Tenax TA® mesh size 35/60, (catalogue number C1-AAXX-5033) thermal desorption 
tubes were used.  These are stainless steel tubes containing a porous polymer resin 
based on 2.6-diphenylene oxide, specifically designed for trapping volatiles or semi-
volatiles from air and in headspace (Sato, et al., 2001).   
A Zebron® ZB-WAX (30m x 0.25mm id x 0.25 film thickness) column was fitted into 
the GC oven.  It is a polar column used for low molecular weight organic acids, both 
the column and TD tubes were used to find volatile substances and specifically 
propanoic acid and butanoic acid (similar to the candidate compounds chosen for 
method development) from a paper on ‘malodour-causing substances of human 
waste’ (Sato, et al., 2001).  
GC-MS Method modifications:  
TD tubes were desorbed by purging for 2 min at ambient temperature then for 10 
min at 250°C.  Volatiles purged from the TD tubes were captured on a cold trap with 
was initially maintained at 10°C then set to a fast heating rate to 250°C with a hold 
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time of 5 min.  (Conditions based on Markes Recommendations Thermal 
Desorption)*i. The GC oven was maintained at 35°C for 5 min then raised at 
increments of 10°C per min to a maximum of 200°C. (The conditions were initially 
based on parameters from Zebron recommendations) *ii and then adjusted to the 
above to give a retention time between 2 and 5 min for both ethyl propionate and 
methyl butyrate.)  Scan, Time 0 to 21.50 min with no solvent delay, selected to 
capture peaks with a low retention time. 
 
2.4.2 Candidate compound Internal Standards 
 
The two candidate compounds were purchased from Sigma-Aldrich; methyl butyrate 
(butanoic acid, methyl ester) – Sigma-Aldrich product no. 19358. Formula C5H10O2.  
Molecular weight 102.13g/mol. Boiling point 102-103°C. Density 0.898g/mLat 25°C. 
CAS no. 623427. 
Ethyl propionate (propanoic acid, ethyl ester) – Sigma-Aldrich product no. 96727. 
Formula C5H10O2.  Molecular weight 102.13g/mol. Boiling point 99°C.  CAS no. 
105373. 
Stock solution of each compound was prepared at 200ng/l and serial dilutions of 
each prepared; - 100, 50, 25, 12.5, 6.25, 3.12 and 0ng/l all diluted in methanol.  This 
range was first chosen to see what peak size would be found from GC-MS analysis 
with the modified method.  A 100μl aliquot of each concentration was dispensed into 
glass vial and sealed.  The solutions were then stored at -80°C until required.  With a 
1µl Hamilton syringe the Tenax TA tube was injected with 0.5µl of each standard and 
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a flow of helium at 500ml/min passed across each tube, analysis by GC-MS was 
using the modified method.   All dilutions were prepared in the same way. 
On finding peaks from an initial run further batchs of solutions of ethyl propionate 
and methyl butyrate were made to cover the range of values found from the faecal 
samples.  These ranged from 4000 to 0 ng/l for methyl butyrate and 1000 to 0 ng/l 
for ethyl propionate in methanol.  Dilutions for ethyl propionate were 1000, 250, 62.5, 
15.62, 3.9, 0.97, 0.49 and 0.12 ng/l.  Dilutions for methyl butyrate were 4000, 1000, 
250, 62.5, 15.62, 3.9, 0.97, 0.49 ng/l.  Several repeats of each dilution were 
analysed on the GC-MS to prepare a standard curve for the quantification of these 
compounds in an actual sample. 
 
2.4.3 Limit of Detection for the Standards 
 
The limit of detection in analysis is the smallest measurable concentration of a 
substance that can be detected with reasonable certainty against the absence of that 
substance for a given method.  This is often described as the LOD (Lower limit of 
detection).  Standard curves for methyl butyrate and ethyl propionate were prepared 
to quantify the LOD (a value of 3SD from the mean gives a 5% or less of a 
probability of the result being wrong).  Calculation of the value of 3SD from the 
lowest mean value the LOD was taken as the lowest concentration relating to the 
blank or intercept as shown in Figures 23 and 24. 
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2.4.4 Comparing retention time for general method and modified method 
 
Analysis from a faecal sample from the general method was picked out for 
comparison.  There was still some of the frozen sample left to do further analysis for 
the modified method to compare methods.   The faecal headspace was drawn 
across a Tenax TA TD tube and analysed with the modified method, this sample 
analysed from the original method contained both methyl butyrate at 10 ng/l and 
ethyl propionate at 243 ng/l.  This was run alongside TD tubes with a similar range 
containing 250, 75 and 1.17 ng/l ethyl propionate and methyl butyrate for 
comparison. 
 
2.4.5 Spiking faecal sample for analysis 
 
Headspace from the same faecal sample was passed onto a further three Tenax TA 
TD tubes and spiked with 250, 75 and 1.17 ng/l respectively of both methyl butyrate 
and ethyl propionate,  and control TD tubes of the same concentrations was also 
analysed to compare with the spiked samples. 
 
2.4.6 Details from patient volunteers – age and gender 
 
Information on age and sex was provided by Addenbrooke’s Hospital for the control 
and disease groups after completion of the analysis. 
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Chapter 3 
 
3.1 Results from patient volunteers - age and gender 
 
Age group and disease type, CD, UC and IBS was plotted into a bar chart as seen in 
Figure 12.  Each disease is more prevalent in the 26 to 35 age range and CD 
continues to be high in the 36 to 45 age range. 
 
 
 
 
Figure 12 Bar chart showing disease type against age.  
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The distribution of males vs. females for groups is shown on Table 5.  
 
Table 5 Number of males to females for each group. 
Group Male Female 
Control 12 8 
IBS 4 27 
UC 13 9 
CD 13 16 
 
 
 
3.2 Candidate compound results 
 
The candidate compound short-list was statistically analysed.   This was carried out 
on pre-treatment faeces initially, as this sample matrix was the basis for choosing 
candidate compounds.  The post treatment faeces groups were then examined for 
the same compounds, followed by breath, blood and urine for the same faecal 
compounds.  There was only one control sample group and this was the same for 
pre and post treatment disease groups. 
 
3.2.1 Faecal samples pre treatment disease groups and controls  
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Box and whisker plots are a statistically descriptive way to show the data, Figure 13 
shows the data range for each of the compounds on the short-list chosen on 
potential biomarkers.  
Figure 13 Box and whisker plots for the candidate compound short-list for faeces to 
compare between control and pre treatment disease groups.   
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The data is very skewed shown by the outlying lines.  Plots have been expanded in 
Figure 14 to show more clearly the median and quartile values.  A high proportion of 
data from each of the plots had outliers to take into account and the ranges of 
absolute amounts were highly varied.   All control samples had smaller amounts of 
the compound than the pre disease groups with the exception of acetone; this was 
expected as it is ubiquitous and a product of the host and bacterial metabolism 
(Turner, et al., 2006).  Non-parametric Kruskal Wallis tests then showed which 
compounds were significant (Table 6 on page 67).  These are marked with an 
asterisk and the median values of each compound for the disease groups were 
calculated from the box and whisker plots. 
Visually comparing between control and pre treatment disease groups in Figure 14, 
the vertical scale has been expanded to allow median and upper and lower quartiles 
to be clearly distinguished.  Whiskers indicating outliers are shown as broken lines 
since many go off the scale. 
 Figure 14 Box and whisker plots for the candidate compound short-list for faeces 
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Table 6 Median and p values (Kruskal Wallis one way analysis of variance) for 
control and pre treatment group candidate compounds.  P values that are 
statistically significant are shown by an asterisk. 
Median (concentration ng/l) P value 
Compound Control CD UC IBS  
acetone 140 94 121 68 0.700 
propanoic acid 5 169 32 80 0.505 
butanoic acid 25 1037 169 473 0.047* 
1-propanol 10 281 94 43 0.002* 
propanoic acid, ethyl 
ester 
0 26 3 0 0.000* 
butanoic acid, methyl 
ester 
0.25 30 7 11 0.013* 
butanoic acid, ethyl 
ester 
0 46 29 1 0.003* 
p-cresol 120 499 221 390 0.177 
indole 9 124 27 41 0.001* 
disulphide dimethyl 30 114 71 57 0.071 
1-butanol 9 115 25 58 0.005* 
butanoic acid, 3-
methyl 
6 141 54 84 0.018* 
phenol 8 40 10 16 0.312 
 
 
The eight significant compounds with a p < 0.05 were treated for a Post hoc analysis, 
the Mann Whitney U-test was used to determine significance between pairs, (Table 
7).  
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Table 7 Post hoc analysis (Mann Whitney U-test) show differences between 
pairs within control and pre treatment disease groups, for candidate 
compounds. Significant values are shown with asterisk. 
  Control Pre CD Pre UC Pre IBS 
Control   0.009* 0.224 0.018* 
Pre CD     0.329 0.708 
Pre UC       0.403 
Pre IBS         
Butanoic acid 
  Control Pre CD Pre UC Pre IBS 
Control   0.0002* 0.019* 0.073* 
Pre CD     0.211 0.028* 
Pre UC       0.309 
Pre IBS         
1-Propanol 
  Control Pre CD Pre UC Pre IBS 
Control   0* 0.015* 0.021* 
Pre CD     0.254 0.031* 
Pre UC       0.488 
Pre IBS         
Propanoic acid, ethyl ester 
  Control Pre CD Pre UC Pre IBS 
Control   0.001* 0.101 0.088 
Pre CD     0.361 0.162 
Pre UC       0.828 
Pre IBS         
Butanoic acid, methyl ester 
  Control Pre CD Pre UC Pre IBS 
Control   0.00* 0.015* 0.109 
Pre CD     0.871 0.049* 
Pre UC       0.25 
Pre IBS         
Butanoic acid, ethyl ester 
  Control Pre CD Pre UC Pre IBS 
Control   0* 0.056 0.045* 
Pre CD     0.035* 0.03 
Pre UC       0.984 
Pre IBS         
Indole 
  Control Pre CD Pre UC Pre IBS 
Control   0* 0.094 0.059 
Pre CD     0.138 0.069 
Pre UC       0.825 
Pre IBS         
1-Butanol 
  Control Pre CD Pre UC Pre IBS 
Control   0.001* 0.093 0.025* 
Pre CD     0.63 0.477 
Pre UC       0.925 
Pre IBS         
Butanoic acid, 3-methyl 
 
 
 
 All eight compounds for control and pre CD pairs were significantly different.  The 
differences between control and pre CD are greater than for any of the other pre 
disease groups when compared with the control samples.    
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3.2.2 Faecal samples post treatment disease groups and controls  
 
Box and whisker plots in Figure 15 interpret the data from each of the compounds on 
the short list chosen for potential biomarkers.                                                     
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Figure 15  Box and Whisker plots for the candidate compound short-list for 
faeces.  Comparison between control and post treatment disease groups 
showing outlying values.   
 
Figure 16 shows the median and quartile ranges.  Again the data was heavily 
skewed similar to pre treatment Box and Whisker plots.  Post treatment groups 
showed absolute amounts to be lower than for the pre treatment groups for most of 
the compounds. 
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Figure 16  Box and Whisker plots for the candidate compound short-list for 
faeces, for comparison between control and post treatment disease groups. 
The vertical scale has been expanded to allow median and upper and lower 
quartiles to be clearly distinguished.  Whiskers indicating outliers are shown 
as broken lines since many go off the scale.  
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Table 8 Median and p values (Kruskal Wallis - one way analysis of variance) for 
control and post treatment group candidate compounds.  P values that are 
statistically significant are marked with an asterisk.                 
Median (concentration ng/l) P value 
Compound Control CD UC IBS  
acetone 140 82 59 91 0.776 
propanoic acid 5 19 62 201 0.333 
butanoic acid 25 54 202 144 0.348 
1-propanol 10 146 9 23 0.203 
propanoic acid, ethyl 
ester 
0 2.1 0 0 0.000* 
butanoic acid, methyl 
ester 
0.25 0.87 0.21 3.9 0.008* 
butanoic acid, ethyl 
ester 
0 2.6 0 0 0.059 
p-cresol 120 480 477 237 0.290 
indole 9 33 13 37 0.714 
disulphide dimethyl      
1-butanol 8.6 72 6 37 0.579 
butanoic acid, 3-
methyl 
6 17 2 112 0.184 
phenol 8 27 14 11 0.288 
 
 
Only two compounds remain significant for post treatment groups (Table 8); 
significant compounds shown with asterisk.  Table 9 shows the differences between 
pairs. 
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Table 9 Post hoc analysis (Mann Whitney U-test) show differences between 
pairs within control and post treatment disease groups, for candidate 
compounds; significant values shown with asterisk. 
  Control Pre CD 
Pre 
UC Pre IBS 
Control   0* 
0.015
* 0.021* 
Pre CD     0.254 0.031* 
Pre UC       0.488 
Pre IBS 
         
Propanoic acid, ethyl ester 
  Control Pre CD Pre UC Pre IBS 
Control   0.001* 0.015* 0.109 
Pre CD     0.871 0.049* 
Pre UC       0.25 
Pre IBS         
Butanoic acid, methyl ester 
 
 
3.2.3 Breath, blood and urine samples pre treatment disease groups and 
controls 
 
These samples were considered for the same short list of candidate compounds as 
the faecal samples.  Box and Whisker plots in Figure 17 show outliers and Figure 18 
shows median values and quartile ranges for acetone and phenol. 
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Acetone was significant in urine and breath, not 
blood. 
  
 
Phenol found significant in blood and breath. 
 
Figure 17 Box and Whisker plots for pre treatment disease groups breath, 
blood and urine; for acetone and phenol.  Boxes are condensed to see outlier 
whiskers. 
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Figure 18 Box and Whisker plots for pre treatment disease groups breath, 
blood and urine; for acetone and phenol.  Plots are expanded to show median, 
upper and lower quartiles. 
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Only two compounds from the short-list were found in these samples they were 
acetone, found in breath and blood but little from urine; and phenol was detected in 
breath, blood and urine but levels were all very low. 
Table 10 shows the median values for acetone and phenol in the sample matrices 
and ambient air to compare with the breath sample.  P values all show to be 
significant except for blood acetone. 
Table 10 Median calculated from box and whisker plots and p values (Kruskal 
Wallis – one way analysis of variance) for control and pre treatment groups for 
acetone and phenol. Sample matrices types include breath (breath samples 
also have an ambient air value for comparison), blood and urine; significant 
compounds shown with an asterisk 
 
 
Comparisons between pairs in groups show a range of significant values as shown 
in Table 11. 
 
  
Compound Sample 
type 
Control CD UC IBS Ambient p-value 
acetone Breath 367 289 426 431 103 0.00* 
acetone Blood 415 530 459 356 - 0.944 
acetone Urine 271 92 229 221 - 0.006* 
phenol Breath 5.3 3.6 3.6 15.7 4.17 0.001* 
phenol Blood 1.8 2.2 2.9 0.8 - 0.002* 
phenol Urine 6.6 1.6 3.0 4.1 - 0.167 
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Table 11 Mann Whitney U-test showing significant values* for pairs within the 
groups for acetone breath and urine and phenol breath and urine. 
 
 
 
 
  
  Control 
Pre 
CD 
Pre 
UC Pre IBS Ambient 
Control   0.338 0.89 0.538 0.002* 
Pre CD     0.13 0.045* 0.0038 
Pre UC       0.762 0* 
Pre IBS         0* 
Ambient           
Acetone Post hoc breath 
  Control Pre CD Pre UC Pre IBS 
Control   0.003* 0.312 0.398 
Pre CD     0.009* 0.02* 
Pre UC       1 
Pre IBS         
Acetone Post hoc urine 
  Control 
Pre 
CD 
Pre 
UC 
Pre 
IBS Ambient 
Control   0.473 0.983 0.007* 0.326 
Pre CD     0.428 0* 0.741 
Pre UC       0.03* 0.309 
Pre IBS         0* 
Ambient           
Phenol Post hoc breath 
  Control Pre CD Pre UC Pre IBS 
Control   0.526 0.077 0.14 
Pre CD     0.049* 0.012* 
Pre UC       0* 
Pre IBS         
     
Phenol Post hoc urine 
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3.2.4 Pre and post treatment faecal samples – Compared 
 
Control and Pre and post treatment groups were compared for the significant 
candidate compounds.  Table 12 and Table 13 show the differences. 
 
Table 12 Statistically significant compounds shown by the *.  Showing the 
comparison between pairs for control and pre treatment disease groups.  
Compound  Control 
vs. Pre 
CD  
Control 
vs. Pre 
UC  
Control 
vs. Pre 
IBS  
Pre 
CD 
vs. 
Pre 
UC  
Pre 
CD vs. 
Pre 
IBS  
Pre 
IBS 
vs. 
Pre 
UC 
1-propanol  *  *  *   *   
butanoic acid, 
methyl ester  
*       
butanoic acid, 
ethyl ester  
*  *    *   
propanoic 
acid, ethyl 
ester  
*  *  *   *   
indole  *   *  *  *   
butanoic acid  *   *     
butanoic acid, 
3 methyl  
*   *     
1-butanol  *       
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Table 13 Statistically significant compounds shown by the *.  Showing the 
comparison between pairs for control and post treatment disease groups.  
Compound  Control 
vs. Post 
CD  
Control 
vs. Post 
UC  
Control 
vs. Post 
IBS  
Post 
CD vs. 
Post 
UC  
Post 
CD vs. 
Post 
IBS  
Post 
IBS vs. 
Post 
UC  
1-propanol       
butanoic acid, 
methyl ester 
  *    *  
butanoic acid, 
ethyl ester 
      
propanoic 
acid, ethyl 
ester 
*     *   
indole       
butanoic acid       
butanoic acid, 
3 methyl 
      
1-butanol       
 
 
There were twenty one instances where significant differences were found between 
pairs for the control and pre treatment disease groups, compared with just four in the 
pairs for the control and the post treatment groups, suggesting that post treatment, 
the disease groups are more similar to the controls. 
 
3.3 Method development results 
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3.3.1. Compound changes for the different methods 
 
A faecal sample from the original method was compared with the standards using 
the modified method.  Retention times and separation between methyl butyrate and 
ethyl propionate were different for the modified method as can be seen from 
comparing faecal sample and standards.   Both compounds had a shorter retention 
time than the original method but separation was slightly longer going from 37 to 62 
seconds.  Figure 19 and Figure 20 show the differences for each method.  Tenax TA 
tubes as controls with the Sigma-Aldrich compounds were compared with the faecal 
samples for the same compounds. 
 
 
          Time in mins 
Figure 19 Chromatogram of a faecal sample from the original GC-MS method.  
Ethyl propionate is shown by the green peak and methyl butyrate is shown by 
the red peak.           
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minutes 
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          Time in mins 
Figure 20 Chromatogram of ethyl propionate (green) and methyl butyrate 
(orange) using the modified GC-MS method. 
 
A new TD tube containing headspace of a faecal sample was analysed with the 
modified method alongside TD tubes containing standards.  The chromatograms are 
shown in Figure 21.   
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          Time in mins 
Figure 21 Chromatograms showing faecal sample (top) and ethyl propionate 
and methyl butyrate (bottom) using the modified GC-MS method. 
 
 
3.3.2 Regression lines for ethyl propionate and methyl butyrate 
 
 
Regression lines, Figures 22 and 23 were produced to determine quantification for 
the chosen standards and their LOD. 
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Figure 22 Regression line for ethyl propionate. 
 
 
 
Figure 23 Regression line for methyl butyrate. 
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Several concentrations of standard were repeated in triplicate to provide sufficient 
data for plotting the regression line.  Linear regression was good for both 
compounds. 
 
3.3.3 Limit of Detection 
  
 
Data from the regression lines gave sufficient information to calculate the lower LOD 
(LLOD) as seen in the graphs below.    
 
Figure 24 LLOD for ethyl propionate (scale has been expanded from the 
regression line shown in figure 21to show lower limits).  
 
LOD = 3.17ng/l 
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Figure 25 LLOD for methyl butyrate (scale has been expanded from the 
regression line shown in figure 22 to show lower limits). 
 
 
The LLOD value was found for both standards.  The standard deviation for the 
lowest concentration of standard used was found and then multiplied by three.  This 
value was extrapolated from the regression line to find the concentration of the 
standard.  The formula for the LLOD is y = mx + c where m is the slope, y is the 
standard deviation x 3 and x is the LLOD.  When the formula is converted to y/m = x 
the value of x or the LOD can be determined.  For ethyl propionate the slope is 
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78384.  When y = 129476 and m = 78384 and the LLOD = 1.65 ng/l.  For methyl 
butyrate when y = 965930 and m = 88084 and the LLOD = 10.97 ng/l. 
 
3.3.4 Faecal samples spiked with methyl butyrate and ethyl propionate 
 
Figure 26 shows the final experiment done to see the effect of spiking TD samples of 
faecal headspace with standards of methyl butyrate and ethyl propionate.  Three 
Tenax TD tubes containing faecal samples were spiked with methyl butyrate and 
ethyl propionate each with the following concentrations, 250, 75 and 1.17 ng/l 
respectively.  These were run with controls TD tubes containing standards with 
concentrations as above.   
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Figure 26 Chromatograms of spiked faeces and compared with ethyl 
propionate and methyl butyrate see key for explanation.  
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Graphs were prepared from the chromatographic data.  Figures 27 and 28 show 
these results.   Peak height was plotted for control tubes (containing standards) and 
spiked faeces containing standards.   
 
Figure 27 Spiked faeces with ethyl propionate and standard. 
 
 
Figure 28 Spiked faeces with methyl butyrate and standard. 
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The above graphs for both ethyl propionate and methyl butyrate display a very good 
correlation between spiked faeces and control standards.  Indicating these 
compounds would make suitable for biomarkers with a GC-MS analytical technique. 
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Chapter 4 
 
 
4.1 Discussion 
 
ATD GC-MS was a chosen method of analysis for this project as it is the best 
screening method for the identification of unknown compounds in complex mixtures, 
and is very sensitive.  As a general method for volatile analysis and TD sample 
collection it provided an efficient way of obtaining breath samples from patients for 
transport to Cranfield for analysis.  The blood, urine and faeces samples also 
transported to Cranfield were stored before analysis could be carried out and 
compared with breath.  Analysis of all samples provided a great number of identified 
compounds for data handling.   
The faecal samples provided the best set of data, more so than the other clinical 
samples and were subsequently used for identification of diagnostic biomarkers.  
Breath, blood and urine were compared with the faecal samples for the same 
candidate compounds found in faeces, but few were detected.  The same procedure 
could be used again to ‘trawl’ through data for new sets of candidate compounds for 
these samples, but is beyond the scope of this project. 
Although there is a lot of literature this area of work is still quite new.  Continuation of 
work from this project would involve testing more clinical samples for the chosen 
compounds to see if they confirm the findings from this study and to improved 
method development for better analytical resolution.  It would be more desirable to 
obtain the analysis from breath or urine rather than from faeces as both are non- 
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invasive and avoid the problems of working with faeces, i.e., that such samples are 
unpleasant for both patient and analyst.   
Sample derivatisation may help to find sulphur based compounds, but best avoided 
as it would require a further step and becomes a laboratory based analysis, a rapid 
non-invasive technique that can be performed at the bedside or in hospital is 
preferable. 
The sample pool of volunteers was taken without any prerequisite preparation from 
them, for example overnight fasting.   A record of medication, diet and smoking and 
drinking habits was recorded which could be used in comparison to the data 
analysed for the clinical samples.  Other factors that may have an effect on gut 
function such as stage of the menstrual cycle although few changes in acetone are 
noticed (Smith, et al., 2006), lifestyle and occupation many be useful for further 
investigation into disease (Houghton, et al., 2009) 
 
4.1.1 Difficulty in choosing biomarkers 
 
IBD is a diverse condition and aetiology not yet precise, resulting in uncertainty of 
the origin of a potential marker compound; VOCs are produced from either the 
commensal bacteria from the gut or from metabolic processes in the host.  Disease 
where markers have traceable origin such as breath isoprene, a biomarker for lipid 
disorders assist confidence in accurate choice.   Isoprene is produced endogenously 
and thought to be part of the biochemical pathway for cholesterol.  (Salerno-Kennedy 
and Cashman, 2005)  IBD is complex by nature and resultant data from sample 
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analysis produced many hundreds of compounds making choice of markers difficult.  
A strategy was adopted to ease the task, and ‘Candidate Compounds’ selected on a 
number of assumptions, firstly from the greatest abundance as seen from analysis, 
secondly informed literature sources and SIFT-MS analysis (Turner,  2006) and last 
from chromatogram inspection using a subset.  Thirteen compounds were found 
from this method from the control and pre-disease groups faecal samples, eight of 
which were found to be statistically significant (see Table 6).  Few of these 
compounds were however found in blood, urine and breath.    
4.1.2 Findings from the candidate compounds  
 
The first of the most abundant compounds was acetone which is ubiquitous and in 
high concentrations as a marker for diabetes (Probert et al 2009).  It was not one of 
the statistically significant compounds but proved the method was reliable.  
Propanoic and butanoic acid was also found in abundance, these are both products 
of fermentation in the gut (Garner, et al., 2007). Control groups had less of both 
acids than disease groups and butanoic acid was greater in disease groups than 
propanic acid.  Post treatment CD had less butanoic acid than pre treatment. 
Compounds chosen from literature were 1-propanol as it is potentially damaging to 
the gut (Garner, et al., 2007). Control groups were lower than pre-treatment CD and 
UC indicating a possibility that this compound is harmful.  The butyrate and 
propionate compounds were higher for all pre-disease groups especially CD and UC 
although these compounds are essentially beneficial to gut health.  Maybe over 
production of them are harmful (Garner, et al., 2007).  Indole was common to all 
faecal samples and levels were lot higher for the pre treatment CD group indicating a 
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higher level may be damaging.  A study by Garner et al 2007 suggested p-cresol 
(4,methylphenol) and dimethyl disulphide were shared by 80% of subjects in a study 
for GI disease.  In the present study they were all found higher in pre disease groups 
than controls. 
Visual inspection compounds 1-butanol and 3-methyl butanoic acid was found to be 
statistically significant with less in controls than for pre disease groups.  Phenol, like 
acetone, is ubiquitous and was not found to be significant. 
In summary all eight candidate compounds that were found significant were all lower 
in the control group than in the pre-treatment disease groups.  Post treatment shows 
a reduction in the candidate compounds and they appeared more similar to control 
samples.  UC and CD generally had a greater amount of the candidate compounds.   
 
4.1.3 Esters found in faeces 
 
Esters make up a large portion of short-chain fatty acids (SCFAs) in the gut and their 
presence in colonic fermentation is a reflection on gut wall esterase activity and 
microbial activity, which may be changed if disease is present (Garner, et al., 2007).  
Of the eight compounds chosen as potential markers three of them were esters; 
methyl butyrate, ethyl butyrate and ethyl propionate.  All three were statistically 
significant between the control and pre CD group, ethyl butyrate and ethyl propionate 
were significant for control and  pre UC, ethyl propionate was significant between 
control and pre IBS and methyl butyrate was significant for control and post IBS.  
These findings indicate that esters do have a role in gut health. 
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4.1.4 Sulphur compounds found in faeces 
 
Few sulphur containing compounds were found by GC-MS.  These were sulphurous 
acid, di(cyclohexylmethyl) ester, hydrogen sulphide, dimethyl disulphide and sulphur 
dioxide.  A few samples contained them but generally none was found.  Dimethyl 
disulphide did appear more often than not and was added to the list of candidate 
compounds.   Sulphurous compounds are implicated in inflammatory conditions, 
faeces from patients with UC contain SRBs and the sulfides produced by them 
interfere with butyrate-dependent energy metabolism (Christl, 1996).   
 By their nature the lack of quantifiable samples of sulphides was probably due to 
their high volatility and other properties such as susceptibility to oxidation, adsorption 
on to glass and rubber and binding to organic molecules. (Richardson,1999).  
Further method development on GC-MS would be necessary to quantify these 
compounds.  A method more suitable to measuring sulphides directly from a breath 
sample has been proven by SIFT-MS.  Significant differences were found between 
all other groups and the CD group.  Having said that, the research was to find many 
sulphur based VOCs that may be indicative of IBD and that could be used as a 
biomarker. Other studies have found sulphides on breath of patients with disease 
(Miekisch and Schubert 2006).  However, interpretation of this has to be done with 
care as sulphur is produced by bacteria in the mouth and thus taking breath samples 
by oral expiration and a nasal sampling regime would overcome this problem.   
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4.1.5 Method development 
 
The two standards chosen for method development were found to have a shorter 
retention time and the separation was slightly better than for the original method.  
This was a favourable result as, if these two compounds were used as biomarkers 
for disease, the analysis time would be shorter and results from a test would be 
faster.  
The calibration curves made from serial dilutions of the standards show good 
repeatability and provide a quantification standard for sample analysis and the lower 
limit of detection for both compounds.  These are encouraging results for further 
work to be carried out on the other significant candidate compounds with the 
expectation they would provide similar results. 
 
4.1.6 Details from patient volunteers age and gender 
 
The age range 26 to 35 is when UC and IBS appear most commonly.  CD affects 
more people in the age range from 26 to 45 years, concurrent with findings for these 
diseases mentioned in Sections1.4.3, 1.4.4 and 1.4.5 and all tail off by the 75 age 
group.   
The most striking difference seen from the data is gender for IBS, females 
outnumber males by 6 times.  The indication is that IBS is affected by the biological 
mechanisms of oestrogen and progesterone during the menstrual cycle, although 
five of these were over the age of 55 and possibly post menopausal (Houghton, et al 
2009).  Also women are affected by stress more than men and IBS is often brought 
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on by stress which causes hormonal imbalances (Cain, 2009).  The number of 
volunteers for this was not enough to draw a firm conclusion and this is just an 
indicator of the possible outcome.  
 
4.1.7 Comments, observations about the project and where it could have been 
better 
 
 Mid way through analysing breath samples high levels of  
propan-2-ol was found.  It was not discovered why this was occurring 
until a visit to Addenbrooke’s where it was noticed that masks were 
being cleaned with propan-2-ol in the treatment room where patients 
were giving breath samples. 
 A comprehensive list prepared with all sample numbers and columns 
for tracking samples could have been drawn up and handed out to all 
concerned with the analysis and handling of samples before analysis 
started, to keep up to date with all samples from collection to 
completion of all laboratory analysis.   
 
4.1.8 Further work 
 
To look at how compounds present ubiquitously in breath and urine vary in 
concentration in different disease groups. 
 To identify markers for breath, blood and urine 
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 Examine the remaining six candidate compounds for method 
development and find LOD 
 Optimise a method development for compounds of interest and identify 
sulphur based compounds 
 Freeze thaw effect on sample storage 
 There is sufficient data still to make a selection of candidate 
compounds from breath, blood and urine similar to ones found in 
faeces. 
 Further comparisons between pre and post treatment disease groups 
would be interesting to see the effect of medication. 
 Quantification on more of the candidate short-list compounds would 
increase quantity of data on possible use of them as diagnostic 
biomarkers. 
                                                                                                                                                                                                                                                                                                                                                                                                                      
5 Conclusions 
 
Volatile compounds in headspace of breath, blood, urine and faeces were analysed 
using ATD-GC-MS to find potential marker compounds for identification of 
gastrointestinal disease. 
 All sample matrices were treated in the same way.  From all the clinical 
matrices the faecal samples provided the most compounds that were used 
for statistical analysis.  Faeces are produced at the ‘site’ of disease and 
made a good place for identification of markers where IBD occurs. 
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 A practical approach to find suitable marker compounds was devised, by 
looking through literature, listing the most abundant compounds found and by 
visual inspection of a representative sample of chromatograms.  Visual 
inspection was used to compare a control with each of the disease groups to 
inspect and identify any differences between them. 
 Eight compounds (ethyl esters of propanoic and butanoic acid, butanoic acid, 
butanioc acid methyl ester, 3-methyl butanoic acid, 1-butanol, 1-propanol and 
indole) were identified from faeces that were significantly different between 
disease groups that could potentially be used as marker compounds. They 
could also discriminate between disease states.  
 Breath, blood and urine were treated in the same way as faeces to find 
suitable markers but only two compounds were found to be significant for 
disease.  Although these compounds were found to be significant the 
confidence that they could be used as biomarkers remains dubious as the 
levels found were very low or indeed often absent from many samples. 
 Of the eight significant compounds, two (butanoic acid methyl ester (methyl 
butyrate) and propanoic acid ethyl ester) were chosen to use for method 
development, which gave a faster retention time, quantification and LLOD. 
 Three methods for VOC analysis was used for the Wellcome Project, GC-MS, 
SIFT-MS and the Breathotron.  GC-MS data provided the best results for 
number and quantity of compounds to choose from. 
 At the beginning of this project it was postulated that sulphur compounds may 
be implicated in disease as they are thought to be damaging to the 
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sulphomucin layer. Unfortunately GC-MS analysis was not capable of 
detecting many of them and further method development would be required. 
 SIFT-MS was found to be capable of detecting sulphur compounds and time 
permitting; further handling of data produced from this method may find 
sulphur markers of interest.   
 Of the compounds identified on GC-MS there were many that do not contain 
sulphur and may have implication with disease, some of which have been 
identified here.  This project has started a process in finding potential markers 
from faeces, and others, yet to be identified in breath, blood and urine to 
provide a rapid method for monitoring disease and the detection of disease in 
its early stages without the need for invasive investigation, preferable for 
patient and clinician alike. 
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5 Appendices 
 
 
5.1 Ethics letter 
 
National Research Ethics Service letter to Professor Hunter dated 4/7/07 
National Research Ethics Service 
Leeds (West)  Research Ethics Commit tee  
A/B Floor, Old Site 
Beds General Infirmary 
Great George Street 
Leeds 
LS1 3EX 
phone: 0113 
392 6788 FE: 
csimile: 0113 
392 2863 
04 July 2007 
Professor John Hunter 
Consultant Physician 
Addenbrooke's Hospital 
Hills Road 
Cambridge 
CB2 2QQ 
Dear Professor Hunter 
Full title of study: 
REC reference number: 
Abnormal sulphur metabolism in the pathogenesis of 
gastrointestinal disease 
07/Q1205/39  
The REC gave a favourable ethical opinion to this study on 24 April 2007. 
Further notification(s) have been received from local site assessor(s) following site-
specific assessment. On behalf of the Committee, I am pleased to confirm the 
extension of the favourable opinion to the new site(s). I attach an updated version 
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of the site lipproval form, listing all sites with a favourable ethical opinion to conduct 
the research. 
R&D approval 
[he Chief Investigator or sponsor should inform the local Principal InvestigatL):- at 
each site of the favourable opinion by sending a copy of this ietter and the attached 
fair
 T
he 
research should not commence at any NHS site until approval from ti :e R&D of ice 
for the relevant NHS care organisation has been confirmed. 
Statement of compliance 
The Committee is constituted in accordance with the Governance 
Arrangements for Research Ethics Committees (July 2001) and complies fully with 
the Standard Operating Procedures for Research Ethics Committees in the UK. 
TO7/Q1205/39 Please quote this number on all corruspond)nce 
Yours sincerely 
• 
Miss Anna 
Fawlk Assistant 
Administrator 
This Research Ethics Committee is  an advisory committee to Y:.,(Kshire and The liurr her Strat, it) i Health 
Authority 
The National Research Ethics Service (NRES) represents the NRES Directorate .-,,,t•;in 
the National Patient Safety Agency and Research Ethics Committees in Eng:.Dn 
 
Form from Leeds (West) Research Ethics Committee for ‘List of sites with a favourable ethical 
opinion’ 
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5.2 Information sheet for volunteers 
 
ABNORMAL SULPHUR METABOLISM IN THE PATHOGENESIS OF 
GASTROINTESTINAL DISEASE vs 2 26/03/07 
'You are being invited to take part in a research study. Before you decide, it is 
important for you to understand why the research is being done and what it 
will involve. Please take time to read the following information carefully. Talk to 
others about the study if you wish. 
 Part 1 tells you the purpose of this study and what will happen to you if you 
take part. 
 Part 2 gives you more detailed information about the conduct of the study. 
Ask us if there is anything that is not clear or if you would like more information. 
Part 1' 
What is the purpose of the study?  
Although many people suffer from ulcerative colitis, Crohn's disease and 
irritable bowel, the causes are still unknown. Mucins are proteins which 
protect the gastrointestinal tract and contain sulphate. Bacteria in the gut 
can remove sulphate from mucin, making the gut leakier and more 
inflamed. The sulphate is converted to hydrogen sulphide which is 
poisonous. Normally, it is rapidly converted to non-toxic compounds. We 
think that all three of these diseases are caused by disruption of this 
process; mucin breakdown may be too fast, hydrogen sulphide may not be 
removed fast enough or mucin synthesis may be faulty. We aim to find the 
precise fault points in the three diseases, looking at bacterial strains, 
individual metabolism and genetic differences in patients and controls. We will 
use complex computer techniques to integrate all our data. This information will 
help to identify individuals 'at risk' of suffering from these diseases and may 
provide improved treatments. 
Why have I been chosen? 
1. Because the health professionals involved in your care believe that you are 
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suffering from one of the conditions in which we are interested, that is to say, 
Inflammatory Bowel Disease, or another bowel disorder which produces similar 
symptoms. 
2.  We are also seeking healthy volunteers who may provide specimens for 
the purposes of comparison. 
Do I have to take part? 
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Taking part in this study is entirely voluntary. If you have been approached as a 
healthy control, be reassured that should you wish not to take part in this 
study, there are many other people we can ask. If you have been approached as 
a patient, your future care will not be compromised if you decide not to take 
part. 
What will happen to me if I take part? What do I have to do? 
We need to ask you a few questions about your health and any medicines you 
may be taking. Then the nurse will arrange to collect a number of samples. You 
will be asked to blow into a plastic balloon to fill it up with your breath. She will 
also take a 20m1 sample of blood and will give you a plastic bottle into which you 
will be asked to pass a specimen of urine. You will also be given a plastic container 
in which we would like to you provide a small quantity of your next bowel motion. 
The breath and the urine will  be analysed to see which chemicals are present 
which contain sulphur. The blood will  be used to measure the activity of  
enzymes involved in sulphur m e t a b o l i s m  a n d  a l s o  f o r  b N A  s t u d i e s  t o  s e e  
i f  t h e  g e n e t i c  m a k e u p  o f  p e o p l e  w i t h  gastrointestinal diseases, is in any 
way different. The stools will  be analysed to see if  they contain bacteria which 
produce a toxic chemical - hydrogen sulphide. 
These samples wil l  not reveal any infor mation about you other than that 
required for this research and all samples will be destroyed after the research 
has been completed. 
What are any possible disadvantages and risks of taking part? 
We do not know of any. 
What are the possible benefits of taking part? 
These tests are completely new, and will not be used by the doctors looking 
after you to help in the management of your case, because we are still 
investigating their potential value. You personally will receive no benefit from 
taking part other than of knowing you may have helped in the understanding of 
these diseases. 
'What will happen if I don't want to carry on with the study?' 
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You may choose to withdraw from the study at any stage. Your data will have 
been identified by an individual number which will also be used to identify the 
samples. If you decide that you wish your data to be withdrawn from the study, 
you should inform one of the research team who will ensure that all information 
collected under your number is destroyed. None of the data will be identified by 
your name, which is known only to the research team at Addenbrooke's.  
Will my taking part in the study be kept confidential? 
Yes. All the information about your participation in this study will be kept 
confidential. (see above for clarification). 
Contact details 
You may phone Mrs Catherine Price on 01223 586739 
Please feel free to ask the research team if you have any further questions.  
Part 2  
Who has reviewed the Study? 
The study has been reviewed and approved by the Leeds (West) Research Ethical 
Committee. 
What happens if new relevant information becomes available during the 
study? 
The study will still be completed in case the further information generated 
by this study further helps our understanding of the diseases concerned 
What if there is a problem? 
If you have a complaint, you may address it to the director of the 
Gastroenterology Department, br Miles Parkes, Box 133, Addenbrooke's Hospital, 
Cambridge CB2 2QQ. 
What if I come to any harm? 
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It is unlikely that you will come to any harm providing these samples, although 
sometimes taking a blood sample can leave a small bruise on the arm. However, if 
anything went wrong, you would be protected by the usual indemnity arrangements 
of the National Health Service. 
Will my taking part in the study be kept confidential? 
Yes, no-one other than the team collecting your samples will know that you have 
taken part. Your GP will not be informed, as at this early stage, the information 
derived from the tests will not be of any help to him and we shall not in any way 
change your treatment. 
All data will be stored anonymously under the terms and conditions of the Data 
Protection Act 1998. Data will be stored in locked cupboard and kept in line 
with Addenbrooke's NHS Trust Data Retention and Destruction Policy' with a 
retention period of 30yrs in line with the Dept of Health Code of Practice 
Management 
Who is organising and paying for the study? 
The study is part of the continuing research program of the Department of 
Gastroenterology at Addenbrooke's Hospital. The analysis on the specimens which 
we collect will be performed in the school of Biosciences at the University of 
Birmingham and at the Dept of Analytical Science and Informatics at the University 
of Cranfield. 
The costs of this study are covered by a grant from the Wellcome Trust - the 
largest private body funding research in the UK. No individual payments are 
made to any of the staff taking part. 
How will the results of the study be publicised?  
In peer-reviewed internationally read medical journals.  
THANK YOU FOR YOUR INTEREST 
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5.3 Volunteer questionnaire 
QUESTIONNAIRE Version 1 31/1/07 
Project: ABNORMAL SULPHUR METABOLISM IN THE PATHOGENESIS OF GASTROINTESTINAL 
DISEASE  
Participant number: 
Today's date: Time of sample: 
PLEASE ANSWER THE FOLLOWING QUESTIONS: 
DOB: 
APP
ROX 
WEI
GHT
: 
APP
RO
X 
HEI
GH
T 
Do you/have or have you ever had? 
Condition YES NO If yes, what - details 
Asthma    
What did you cat? 
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Diabetes    
Metabolic Disorder    
Any other long term medical condition     
DO YOU FEEL WELL TODAY? 
If not what is wrong (eg: cold, sore throat, headache etc) 
BEFORE YOU SUPPLY THIS URINE SAMPLE HOW LONG AGO WAS IT THAT 
YOU: I. Ate a standard meal (breakfast, lunch or dinner) — HOURS 
What did you eat? 
2. At a light snack (sandwich, crisps, sweets etc) -- HOURS 
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5.4 SOP for GCMS 
 
 
 
This method is for the TD tube containing the sample to be analysed and have a 
brass fitting attached at either end. 
 
1. Make a record of the TD tube number and place in order into a tray, starting 
with a blank and standard then samples and finish with a standard and blank.  
2.  Remove both brass fittings and gently pack silanised glass wool into tube end 
nearest the grooved notch.  The tube contains packing material and a small 
circular gauze near the grooved notch that can be easily dislodged if pushed 
with forceps.  Standards and sample tubes are packed with silanised glass 
wool but blanks are left empty. 
3. Replace with PTFE end caps.  
4. Set helium line to flow at 500ml/min. 
5. Leave blanks aside then with the remainder of the tubes taking one tube at a 
time, remove both PTFE end caps, and screw notched end of tube into nut 
assembly on helium line and secure firmly.   
6. With a Hamilton syringe dispense 50ng of standard (d8-Toluene), through 
septum onto silanised glass wool plug in the tube. 
7. Open flow tap and leave for 20 seconds. Switch off flow tap and remove tube 
from flow line. 
8. Remove silanised glass wool and replace both PTFE end caps. 
9. Place tubes onto the ATD carousel, starting at number 1 (number sequence 
displayed on front edge of carousel).  Place tube with notched end away from 
the carousel number display. 
 
 
Setting up GC/MS for sample analysis 
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Open ‘TurboMasss 4.1 – METHOD 2007022.spl’ 
 
1. Find ‘Samples’ on tool bar, click and then choose ‘Add’. 
2. Type in the number of tubes you are analysing plus two (this for two cycles for 
cold trap cleaning) 
3. Click ‘OK’ and the screen will add tube numbers to list in ‘File Name’ column. 
4. The system copies the previous ‘Sample ID’ and ‘File Text’ data so highlight 
the area to delete then press ‘delete’. 
5. Type in ‘trap’ into both columns then for each, copy below, see Figure  below.  
Then type in tube codes and sample identification. 
6. The ‘MS Method’ and ‘GC Method’ columns are both set to add in default 
methods (PILARTD) and (CWdevel) these are the general methods for most 
analysis. 
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Figure 29 Turbomass sample list 
7. Open ‘pe test ATS – ATD Control (COM2)’ window. 
8. Select ‘Sequence Editor’ tab 
9. Select ‘Trap condition 00’ and drag and drop under ‘Method Name’ box.  
Repeat.  Then drag and drop ‘Tenax Carbotrap desorb 00’.  Change ‘Last 
Tube’ to the number of tubes for analysis.  (use right arrow key to move blue 
highlight box to next box, this just makes sure the last tube number has been 
entered) 
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 Figure 30 ATD control sequence editor  
10. Re-open ‘TurboMass 4.1’ window and highlight your samples for analysis and 
press ‘►’.  Observe the ‘General Status’ box for GC this will indicate when run 
will start.  
11. ‘Start sample list run’ window will open.  Check run sample numbers are 
correct and press ‘OK’. 
12. ‘TurboMass’ window will open, then press ‘Yes’ if OK. 
13. Re-open ‘pe test. ATS – ATD Control (COM2)’ window and press the green 
button. 
14. Leave to run, check after about 30 minutes to make sure run has initiated. 
15. Run progress can be checked by selecting status screen, this shows in 
diagram what is happening.  White boxes under ‘Primary Desorb’ and 
‘Secondary Desorb’ have pre-set conditions and yellow boxes show actual 
readings  
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Figure 31 Tenax-Carbotrap Intital B - ATD control (COM2) 
16. Fill in log book with run details. 
17. Record tubes in TD log book with date and tube contents e.g. Blank, Standard 
or Sample + code. 
18. When run has finished check results and conditions of run and report in log.   
 
Headspace from urine, blood and faecal samples after analysis on the SIFT-MS was 
drawn from the bag by using a FLEC® constant-flow pump purchased from Markes 
International  using a flow rate of 100ml for 5 minutes and passed onto a TD tube, 
the tube was then stored at 4° C prior to GC-MS analysis. 
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Table 14  List of Compounds found in a blank sample balloon (balloon with 
zero grade air and incubated for 30 mins, 500ml headspace drawn across a 
thermal desorption tube and internal standard, Toluene D-8, for GC-MS 
analysis) 
 
Name R.T. Amount 
Absolute 
amount 
Cyclotrisiloxane, hexamethyl- 1.954 9.33% 16 
2-Butanone 2.198 0.41% 1 
Ethanol, 2-fluoro- 2.314 0.20% 0 
1,3-Dioxolane, 2-methyl- 2.73 1.99% 3 
Toluene-D8 4.117 58.70% 100 
Pentacarbonyltris(trimethylsilyl)stibinemolybdenum 17.976 0.43% 1 
3-(4-Buthoxybenzylthio)-1,2,4-(4H)-triazole 19.166 0.33% 1 
(3-Cyclohexyl-5-hydroxy-5-trifluoromethyl-4,5-dihydro-pyrazol-1-
yl)-(4-methoxy-phenyl)-methanone 19.172 1.61% 3 
p-Anisic acid, 4-nitrophenyl ester 19.178 1.70% 3 
3-Ethoxy-1,1,1,7,7,7-hexamethyl-3,5,5-
tris(trimethylsiloxy)tetrasiloxane 19.631 0.32% 1 
Allophanic acid, phenyl ester 19.798 0.33% 1 
Carbamodithioic acid, acetyl-, methyl ester 20.44 0.31% 1 
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